REPORT OF THE FIFTEENTH SESSION OF THE CODEX COMMITTEE ON RESIDUES OF VETERINARY DRUGS IN FOODS

Washington D.C., USA, 26-29 October 2004

Note: This report includes Codex Circular Letter CL 2004/50-RVDF
TO: Codex Contact Points
   Interested International Organizations

FROM: Secretary, Codex Alimentarius Commission,
      Joint FAO/WHO Food Standards Programme
      Viale delle Terme di Caracalla, 00100 Rome, Italy

SUBJECT: Distribution of the Report of the Fifteenth Session of the Codex Committee on
          Residues of Veterinary Drugs in Foods (ALINORM 05/28/31)

The report of the Fifteenth Session of the Codex Committee on Residues of Veterinary Drugs in Foods
(CCRVDF) is attached. It will be considered by the 28th Session of the Codex Alimentarius Commission
(Rome, 4 – 9 July 2005)

PART A: MATTERS FOR ADOPTION BY THE 28th SESSION OF THE CODEX ALIMENTARIUS
        COMMISSION AT STEP 8 AND STEPS 5/8

1. Draft Maximum Residue Limits at Step 8 (ALINORM 05/28/31, Appendix II)
2. Proposed Draft Maximum Residue Limits at Steps 5/8 (ALINORM 05/28/31, Appendix III)
3. Proposed Draft Code of Practice to Minimize and Contain Antimicrobial Resistance
   (ALINORM 05/28/31, Appendix VIII)

Governments and interested international organizations are invited to comment on the above texts and
should do so in conformity with the Procedures for the Elaboration of Codex Standards and Related Texts
forwarded to the Secretary, Codex Alimentarius Commission, Viale delle Terme di Caracalla, 00100
Rome, Italy (fax +39 06 57054593; e-mail codex@fao.org - preferably), not later than 30 March 2005.

PART B: MATTERS FOR ADOPTION BY THE 28th SESSION OF THE CODEX ALIMENTARIUS
        COMMISSION AT STEP 5

4. Proposed Draft Maximum Residue Limits at Step 5 (ALINORM 05/28/31, Appendix V)

Governments and interested international organizations are invited to comment on the above texts and
should do so in conformity with the Procedures for the Elaboration of Codex Standards and Related Texts
forwarded to the Secretary, Codex Alimentarius Commission, Viale delle Terme di Caracalla, 00100
Rome, Italy (fax +39 06 57054593; e-mail codex@fao.org - preferably), not later than 30 March 2005.
PART C: REQUEST FOR COMMENTS/INFORMATION

5. Information on veterinary drugs without ADI/MRL. The 15th CCRVDF in discussing the recommendations of the Joint FAO/WHO Technical Workshop on Residues of Veterinary Drugs without ADI/MRL (Bangkok, Thailand, 24-26 August 2004) related to the establishment of priorities, agreed to establish a Working Group to develop recommendations on how to deal with these compounds. The Working Group will carry out specific tasks on the basis of the information received by governments and interested international organizations on: i) all compounds with no Codex MRLs used at national level for food animals; ii) compounds in use that raise health concerns; iii) compounds in use that create trade problems; compounds recommended for inclusion in a negative list and the reasons for their inclusion in that list; iv) national or regional MRLs (if any); v) other tolerances or application of an analytical limit of detection or determination (ALINORM 05/28/31, paras 172-174)

Governments and interested international organizations wishing to provide information on the above should do so in writing to the U.S. Codex Office, Food Safety and Inspection Service - US Department of Agriculture, Room 4861 South Building, 14000 Independence Ave., SW - Washington, DC, 2025 USA (fax. +1 202 720 3157; e-mail: uscodex@usda.gov) with a copy to the Secretary, Codex Alimentarius Commission, Viale delle Terme di Caracalla, 00100 Rome, Italy (fax +39 06 57054593; e-mail codex@fao.org - preferably), not later than 28 February 2005.
## Contents

**SUMMARY AND CONCLUSIONS** ........................................................................................................ page vi

**LIST OF ABBREVIATIONS** ............................................................................................................. page viii

**REPORT OF THE 15TH SESSION OF THE CODEX COMMITTEE ON RESIDUES OF VETERINARY DRUGS IN FOODS** ........................................................................................................ page 1

**SUMMARY STATUS OF WORK** .................................................................................................... page 22

---

### Paragraph

**OPENING OF THE SESSION** ........................................................................................................ 1 - 2

**ADOPTION OF THE AGENDA (Agenda Item 1)** .......................................................................... 3 - 6

**APPOINTMENT OF THE RAPPORTEUR (Agenda Item 2)** .......................................................... 7

**MATTERS REFERRED/OF INTEREST TO THE COMMITTEE ARISING FROM THE CODEX ALIMENTARIUS COMMISSION AND OTHER CODEX COMMITTEES AND TASK FORCES (Agenda Item 3)** ...................................................................... 8 - 20

**REPORT OF THE 60TH AND 62ND MEETINGS OF JOINT FAO/WHO EXPERT COMMITTEE ON FOOD ADDITIVES (Agenda Item 4)** ........................................................................................................ 21 - 40

**REPORT OF OIE ACTIVITIES, INCLUDING THE HARMONIZATION OF TECHNICAL REQUIREMENTS FOR THE REGISTRATION OF VETERINARY MEDICINAL PRODUCTS (VICH) (Agenda Item 5)** ........................................................................................................ 41 - 49

**CONSIDERATION OF MAXIMUM RESIDUES LIMITS FOR VETERINARY DRUGS (Agenda Item 6)** ........................................................................................................ 50 - 92

**PROPOSED DRAFT CODE OF PRACTICE TO MINIMIZE AND CONTAIN ANTIMICROBIAL RESISTANCE (Agenda Item 7)** ........................................................................................................ 93 - 116

**PROPOSED DRAFT REVISED GUIDELINES FOR THE ESTABLISHMENT OF REGULATORY PROGRAMME FOR THE CONTROL OF VETERINARY DRUG RESIDUES IN FOODS (INCLUDING APPENDIX ON THE PREVENTION AND CONTROL OF VETERINARY DRUG RESIDUES IN MILK AND MILK PRODUCTS (Agenda Item 8)** ........................................................................................................ 117 - 122

**PROPOSED DRAFT REVISED PART II “GENERAL CONSIDERATIONS ON ANALYTICAL METHODS FOR RESIDUES CONTROL OF THE CODEX GUIDELINES FOR THE ESTABLISHMENT OF REGULATORY PROGRAMME FOR THE CONTROL OF VETERINARY DRUG RESIDUES IN FOODS** (Agenda Item 9) ........................................................................................................ 123 - 132

**DISCUSSION PAPER ON RISK MANAGEMENT METHODOLOGIES, INCLUDING RISK ASSESSMENT POLICIES IN THE CODEX COMMITTEE ON RESIDUES OF VETERINARY DRUGS IN FOODS (Agenda Item 10)** ........................................................................................................ 133 - 153

**REVIEW OF PERFORMANCE-BASED CRITERIA FOR METHODS OF ANALYSIS FOR VETERINARY DRUG RESIDUES IN FOODS (Agenda Item 11a)** ........................................................................................................ 154

**IDENTIFICATION OF ROUTINE METHODS OF ANALYSIS FOR VETERINARY DRUG RESIDUES IN FOODS (Agenda Item 11b)** ........................................................................................................ 155 - 160

**CONSIDERATION OF THE PRIORITY LIST OF VETERINARY DRUGS REQUIRING EVALUATION OR RE-EVALUATION (Agenda Item 12)** ........................................................................................................ 161 - 176

**OTHER BUSINESS AND FUTURE WORK (Agenda Item 13)** ....................................................... 177

**DISCUSSION PAPER ON ROUNDING OF ADIs FOR VETERINARY DRUGS PRIOR TO SETTING MRLS (Agenda Item 13a)** ........................................................................................................ 178 – 184

**DATE AND PLACE OF NEXT SESSION (Agenda Item 14)** .............................................................. 185 - 186
Appendix I: List of Participants ................................................................. page 24
Appendix II: Draft Maximum Residue Limit for Veterinary Drugs (at Step 8 of the Elaboration Procedure) ................................................. page 43
Appendix III: Proposed Draft Maximum Residue Limit for Veterinary Drugs (at Steps 5/8 of the Elaboration Procedure) ............................................. page 46
Appendix IV: Draft Maximum Residue Limit for Veterinary Drugs (at Step 7 of the Elaboration Procedure) ....................................................... page 47
Appendix V: Proposed Draft Maximum Residue Limit for Veterinary Drugs (at Step 5 of the Elaboration Procedure) ............................................. page 48
Appendix VI: Proposed Draft Maximum Residue Limit for Veterinary Drugs (at Step 4 of the Elaboration Procedure) ............................................. page 50
Appendix VII: Discontinued Work on Draft and Proposed Draft Maximum Residue Limit for Veterinary Drugs ......................................................... page 51
Appendix VIII: Proposed Draft Code of Practice to Minimise and Contain Antimicrobial Resistance (at Steps 5/8 of the Elaboration Procedure) ....... page 53
Appendix IX: Priority List of Veterinary Drugs Requiring Evaluation or Re-evaluation .... page 68
SUMMARY AND CONCLUSIONS

The Fifteenth Session of the Codex Committee on Residues of Veterinary Drugs in Foods reached the following conclusions:

MATTERS FOR ADOPTION BY THE 28th SESSION OF THE CODEX ALIMENTARIUS COMMISSION:

The Committee recommended to the Commission:

Adoption of texts at Step 8
- Draft MRLs for cyhalothrin, flumequine, neomycin and dicyclanil (para. 92 and Appendix II).

Adoption of texts at Steps 5/8
- Proposed draft MRLs for imidocarb (para. 92 and Appendix III);
- Proposed draft Code of Practice to Minimise and Contain Antimicrobial Resistance (para. 117 and Appendix VIII).

Adoption of texts at Step 5
- Proposed draft MRLs for flumequine (in black tiger shrimp), pirlimycin, cypermethrin and alpha-cypermethrin and doramectin (in cow’s milk) (para. 92 and Appendix V).

MATTERS FOR CONSIDERATION BY THE 28th SESSION OF THE CODEX ALIMENTARIUS COMMISSION:

The Committee recommended:

Proposal for new work
- Priority List of Veterinary Drugs Requiring Evaluation of Re-evaluation (para. 171 and Appendix IX).

Revocation of Codex MRL
- Codex MRLs for carbadox (para. 27).

Discontinuation of work on MRL
- Draft and Proposed draft MRLs for phoxim (in cattle tissues and cow’s milk), cefuroxime (in cow’s milk), cypermethrin (in sheep tissues) and alpha-cypermethrin (in cattle and sheep tissues and cow’s milk) (para. 93 and Appendix VII).

MATTERS OF INTEREST TO THE COMMISSION:

The Committee agreed:

Draft and proposed draft MRLs
- To retain at Step 7 the draft MRLs for trichlorfon (metrifonate) and at Step 4 proposed draft MRL for ractopamine (para. 92 and Appendices IV and VI);

Proposed draft revised Guidelines for the Establishment of a Regulatory Program for the Control of Veterinary Drug Residues in Foods
- To return the proposed draft revision of the Guidelines to Step 2, for redrafting by a Working Group based on the written comments submitted and the discussion at the current session, for circulation, comments and consideration at its 16th Session (para. 123).
Part II of the proposed draft revised Guidelines for the Establishment of a Regulatory Program for the Control of Veterinary Drug Residues in Foods

- To return the proposed draft revision of Part II of the Guidelines to Step 2 and that a Working Group would redraft all sections on methods of analysis and sampling in the Guidelines (Part I, II and III) for comments and further consideration at its 16th Session. The Committee noted that the sections would be revised concurrently with the main body of the Guidelines concerning regulatory programmes and agreed that close coordination should be exercised between the relevant Working Groups. (paras 132-133).

Review of Performance-based Criteria for Methods of Analysis for Residues of Veterinary Drugs in Foods

- To use the document prepare for its 14th Session (CX/RVDF 03/10) as the resource document for the revision pf Part II and part III of the Guidelines and that there would be no more work on this document (para. 155)

Risk Management Methodologies, including Risk Assessment Policies in the Codex Committee on Residues of Veterinary Drugs in Foods

- That the discussion paper should be redrafted as a working document for in the Procedural Manual, with a view to its finalisation at its next Session. The Committee agreed that the document should be redrafted by a Working Group taking into account written comments, the discussion at the present Session and the recommendations of the Joint FAO/WHO Technical Workshop on Residues of Veterinary Drugs without ADI/MRL where applicable, for comments and consideration at its 16th Session (para. 153).

Identification of Routine Methods of Analysis for Veterinary Drug Residues

- To circulate the list of methods of analysis for veterinary drug residues for comments and for inclusion of additional methods and considered further at its 16th Session, with a view to the finalisation of suitable methods for adoption as Codex methods for the determination of veterinary drug residues (para. 159).

Recommendations for Residues of Veterinary Drugs without ADI/MRLs

- To establish a Working Group to develop recommendations on how to deal with compounds for which an ADI or MRL could not be set. The Committee agreed that a Circular Letter would be sent to collect the following information: all compounds with no Codex MRLs used at the national level for food animals; compounds in use that raise health concerns; compounds in use that create trade problem; compounds recommended for inclusion in a negative list and the reason for inclusion in that list; national or regional MRLs; and other tolerances or application of an analytical limit for detection of determination. And that, on the basis of the information received, a Working Group, would establish two lists of compounds; establish criteria for their prioritisation; prioritise the listed compound for future consideration; develop recommendation of how to proceed with their consideration; where necessary, discuss other risk management option; and develop a timetable for action for consideration at its 16th Session (paras 174-176).

Rounding of ADIs for Veterinary Drugs prior to setting MRLs

- To set MRLs using the calculated ADI and publish the calculated ADI as JECFA’s recommendation and to refer its discussion to JECFA. The Committee agreed to apply this policy to future evaluation by JECFA and that the recalculation of MRLs for substances already considered by JECFA would be requested on a case-by-case basis through the routine procedure of prioritization of substances for JECFA evaluation/re-evaluation (paras 184-185)

Ad hoc Working Groups on Methods of Analysis and Sampling and on Priorities

- To convene the ad hoc Working Group on Methods of Analysis and Sampling and on Priorities prior to its next Session under the Chairmanship of Australia (paras 160 and 177)
### List of Abbreviations Used in this Report

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADI</td>
<td>Acceptable Daily Intake</td>
</tr>
<tr>
<td>ALA</td>
<td>Asociacion Latinoamericana de Avicultura/Latino-American Poultry Association</td>
</tr>
<tr>
<td>AOAC</td>
<td>Association of Analytical Chemists</td>
</tr>
<tr>
<td>bw</td>
<td>body weight</td>
</tr>
<tr>
<td>CAC</td>
<td>Codex Alimentarius Commission</td>
</tr>
<tr>
<td>CAC/RCP</td>
<td>Codex Alimentarius Commission / Recommended Code of Practice</td>
</tr>
<tr>
<td>CAC/GL</td>
<td>Codex Alimentarius Commission / Guidelines</td>
</tr>
<tr>
<td>CCMAS</td>
<td>Codex Committee on Methods of Analysis and sampling</td>
</tr>
<tr>
<td>CCPR</td>
<td>Codex Committee on Pesticide Residues</td>
</tr>
<tr>
<td>CCRVDF</td>
<td>Codex Committee on Residues of Veterinary Drugs in Foods</td>
</tr>
<tr>
<td>CI</td>
<td>Consumers International</td>
</tr>
<tr>
<td>CL</td>
<td>Circular Letter</td>
</tr>
<tr>
<td>CRD</td>
<td>Conference Room Document</td>
</tr>
<tr>
<td>EC</td>
<td>European Community</td>
</tr>
<tr>
<td>FAO</td>
<td>Food and Agriculture Organization of the United Nations</td>
</tr>
<tr>
<td>IAEA</td>
<td>International Atomic Energy Administration</td>
</tr>
<tr>
<td>IDF</td>
<td>International Dairy Federation</td>
</tr>
<tr>
<td>IFAH</td>
<td>International Federation for Animal Health</td>
</tr>
<tr>
<td>IPCS</td>
<td>International Programme on Chemical Safety</td>
</tr>
<tr>
<td>IUPAC</td>
<td>International Union of Pure and Applied Science</td>
</tr>
<tr>
<td>JECFA</td>
<td>Joint FAO/WHO Expert Committee on Food Additives</td>
</tr>
<tr>
<td>JMPR</td>
<td>Joint FAO/WHO Meeting on Pesticide Residues</td>
</tr>
<tr>
<td>MRL</td>
<td>Maximum Residue Limit</td>
</tr>
<tr>
<td>MRLVD</td>
<td>Maximum Residue Limit for Veterinary Drug</td>
</tr>
<tr>
<td>OIE</td>
<td>Office International des Epizooties /World Organization for Animal Health</td>
</tr>
<tr>
<td>OIRSA</td>
<td>Organismo Internacional Regional de Sanidad Agropecuaria/Regional International Organization for Plant Protection and Animal Health</td>
</tr>
<tr>
<td>QA</td>
<td>Quality Assurance (systems)</td>
</tr>
<tr>
<td>TRS</td>
<td>Technical Report Series</td>
</tr>
<tr>
<td>TMDI</td>
<td>Theoretical Maximum Daily Intake</td>
</tr>
<tr>
<td>US</td>
<td>United States of America</td>
</tr>
<tr>
<td>VICH</td>
<td>International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
</tbody>
</table>
OPENING OF THE SESSION

1. The 15th Session of the Codex Committee on Residues of Veterinary Drugs in Foods was held from 26-29 October 2004 in Washington D.C., at the kind invitation of the Government of the United States of America. The Session was chaired by Dr Stephen Sundlof, Director, Center for Veterinary Medicine, United States Food and Drug Administration. The Session was attended by delegates from 45 Member countries and 1 Member organization and Observers from 11 international organizations. The list of participants is attached to this report as Appendix I.

2. Dr F. Edward Scarbrough, Manager of the US Codex Office, United States Department of Agriculture, opened the Session.

ADOPTION OF THE AGENDA (Agenda Item 1)1

3. The Commission adopted the Provisional Agenda as its Agenda for the Session. The Committee changed the order of discussion as follows:

   • Agenda Item 5 “Report of the OIE activities, including the Harmonization of Technical Requirements for Registration of Veterinary Medicinal Products” before Agenda Item 4 “Report of the 60th and 62nd Meetings of the Joint FAO/WHO Expert Committee on Food Additives”;

   • Agenda Item 13 (a) “Discussion Paper on Rounding of ADIs for Veterinary Drugs prior to Setting of MRLs” prior to Agenda Item 6 “Consideration of Maximum Residue Limits for Veterinary Drugs”;

   • Agenda Item 10 “Discussion Paper on Risk Management Methodologies, Including Risk Assessment Policies, in the Codex Committee on Residues of Veterinary Drugs in Foods” prior to the Agenda Items related to the revision of the Guidelines for the Establishment of a Regulatory Program for the Control of Veterinary Drugs Residues in Foods, i.e. Agenda Items 8, 9 and 11.

   • Agenda Item 7 “Proposed draft Code of Practice to Minimise and Contain Antimicrobial Resistance” prior to Agenda 12 “Consideration of the Priority List of Veterinary Drugs Requiring Evaluation or Re-evaluation”.

4. The resulting order of the Agenda Items was: 1, 2, 3, 5, 4, 13(a), 6, 10, 8, 9, 11, 7, 12, 13 and 14.

5. The Committee agreed to consider a document submitted on a FAO/IAEA Workshop on “Strengthening Capacities for Implementing Codex Standards, Guidelines and the Recommended International Codes of Practice for the Control of the Use of Veterinary Drugs” under Agenda Item 13 “Other Business and Future Work”. It further agreed to consider the recommendations of the FAO/WHO Technical Workshop on Residues of Veterinary Drugs without ADI and/or MRLs prior to consideration of Agenda Item 10 “Discussion Paper on Risk Management Methodologies, Including Risk Assessment Policies, in the Codex Committee on Residues of Veterinary Drugs in Foods”.

6. The Delegation of the European Community presented CRD 4 on the division of competence between the European Community and its Member States according to paragraph 5, Rule II.5 of the Rules of Procedure of the Codex Alimentarius Commission.

APPOINTMENT OF RAPPORTEUR (Agenda Item 2)

7. The Committee appointed Dr Jack Kay (United Kingdom) to serve as Rapporteur to the Session.

---

1 CX/RVDF 04/15/1 and CRD 4 (Division of Competence between the European Community and its Member States)
MATTERS REFERRED/OF INTEREST TO THE COMMITTEE ARISING FROM THE CODEX ALIMENTARIUS COMMISSION AND OTHER CODEX COMMITTEES AND TASK FORCES
(Agenda Item 3)

MATTERS FROM THE CODEX ALIMENTARIUS COMMISSION AND OTHER CODEX COMMITTEES AND TASK FORCES

8. The Committee noted several of the general decisions by the 26th and 27th Sessions of the Codex Alimentarius Commission in relation to: Amendments to the Procedural Manual; Financial and Budgetary Matters; Strategic Plan (2008-2013); Implementation of the Joint FAO/WHO Evaluation of the Codex Alimentarius; Risk Analysis; Antimicrobial Resistance; Relations between the Codex Alimentarius Commission and other International Organizations; Provision of Scientific Advice to the Codex System; and the FAO/WHO Trust Fund for Enhanced Participation in Codex.

9. The Committee noted that the 26th Session of the Codex Alimentarius Commission had returned the draft temporary MRLs for phoxim in cattle tissues and cow’s milk to Step 6, pending JECFA re-evaluation; had withdrawn the proposed temporary MRLs for lincomycin in cattle and sheep tissues; and had advanced the proposed draft temporary MRLs for cyhalothrin only to Step 6, pending further re-consideration by JECFA.

10. The 26th Session of the Commission adopted all the other draft and proposed draft MRLs at Steps 8, 5/8 and 5 as recommended by the 13th and 14th Session of the Committee on Residues of Veterinary Drugs in Foods. The Commission adopted the draft amendments to the Glossary of Terms and Definitions at Step 5 of the Accelerated Procedure.

Committee on Fish and Fishery Products

11. The Committee considered the two sections of the draft Code of Practice for Fish and Fishery Products, related to the administration of veterinary drugs, namely: 6.3.1 Feed Supply and 6.3.2 Veterinary Drugs in the Aquaculture Section. In this regard, the Committee recommended that the Committee on Fish and Fishery Products refers to the relevant Codes of Practice, instead of listing specific recommendations under the heading “Technical Guidance”. The Representative of the OIE underscored the importance of taking into account the work of the OIE Working Group on food safety that is preparing Good Farming Practices, which also includes aquaculture.

MATTERS FROM FAO AND WHO

Progress report of the FAO/WHO Consultative Process on the Provision of Scientific Advice to Codex and Member Countries

12. The Committee was informed about the advance made in the implementation of this important process and the activities in place to increase the transparency and efficiency of expert meetings. The Committee took note that FAO and WHO were preparing a Framework for the provision of scientific advice that would be publicly available next year as well as discussion papers to address procedures for the selection of experts, openness of scientific meetings and procedures for use of data. The Representative of FAO indicated that the final step of the consultative process would be implemented next year if the necessary resources are available.

13. The Committee took note that due to the increased requests for scientific advice coming from Codex subsidiary bodies there was an urgent need to establish criteria to set priorities by Codex. In the absence of such criteria, FAO and WHO would continue planning expert meetings and consultations considering the following criteria: a) clear scope of the advice requested; b) urgency of the advice requested; c) availability of required data or commitment of countries to provide such data; and d) availability of financial resources or institutional support. Based on these criteria FAO/WHO were able to organize a workshop on veterinary drug residues without ADI/MRL and two meetings on antimicrobial resistance to provide the advice needed for the present CCRVDF session.

CX/RVDF 04/15/2; CX/RVDF 04/15/2, Add-1; CRD 7 (European Community)
FAO/WHO Expert Meetings and Consultations

Antimicrobial resistance resulting from non-human usage of antimicrobials

14. The Committee was informed about the results of the two meetings organized by FAO/OIE/WHO on this subject. The first meeting conducted a scientific assessment considering all non-human uses of antimicrobials in animals and plants and the second meeting discussed some risk management options to prevent/control these risks. The Committee took note that results of these meetings were a valuable input for the discussion of the proposed draft Code of Practice to Minimize and Contain Antimicrobial Resistance.

Joint FAO/WHO Technical Workshop on Residues of Veterinary Drugs without ADI/MRL

15. The Committee was informed about the recommendations made at the FAO/WHO Technical Workshop on Residues of Veterinary Drugs without ADI/MRL, held in Bangkok, Thailand, in August 2004. The Workshop was organized at the request of the 26th Session of the Codex Alimentarius Commission, the Government of Thailand and the FAO’s proposal to examine the disruptions in trade that occurred in 2001/2002 caused by the detection of trace amounts of chloramphenicol and nitrofuran metabolites in foods of animal origin.

16. The Workshop discussed the following issues: progress of analytical methods and impact on international trade; analysis and management of risk of low level residues; risk assessment by JECFA; regulatory framework at the national and regional level; international regulatory framework provided by Codex and WTO; and capacity building issues.

17. The Workshop formulated five blocks of recommendations, most of which were relevant for the present work of the CCRVDF and would be addressed during the discussion of Agenda Items 8 – 12.

18. The Committee took note that recommendations of the Workshop related to the need for advice on the use of veterinary drugs in aquaculture, which would be addressed through a technical meeting to be organized by FAO/WHO/OIE with the collaboration of interested governments/institutions if extra budgetary resources could be identified.

Joint FAO/WHO Project to Update the Principles and Methods for the Assessment of Chemicals in Foods

19. The Committee was informed about the advances made in this project. Draft chapters have been prepared on several topics and for others, including exposure assessment and dose-response assessment, technical workshops are in preparation or were held recently. The recent IPCS workshop on dose-response modelling resulted in recommendations which will be implemented at the next JECFA meeting on contaminants. Experience from this meeting might impact on future JECFA meetings dealing with veterinary drug residues.

20. All draft chapters will be posted on the FAO/WHO websites for comments.

REPORT OF THE 60TH AND 62ND MEETINGS OF THE JOINT FAO/WHO EXPERT COMMITTEE ON FOOD ADDITIVES (Agenda Item 4)

Report of the 60th JECFA Meeting

21. JECFA evaluated seven veterinary drugs, two antimicrobial agents (neomycin and flumequine), three insecticides (deltamethrin, dicyclanil and trichlorfon), an antiprotozoal agent (imidocarb) and one production aid (carbadox). In addition, the 60th JECFA elaborated on a number of general principles.

Assessment of Carcinogenic Risk

22. JECFA adopted the IPCS Conceptual Framework for Evaluating a Mode of Action for Chemical Carcinogenesis as part of its working practices and proposed a stepwise approach to consider the risk posed by veterinary drugs that are carcinogenic to experimental animals.

3 WHO TRS 918 (60th JECFA) and WHO TRS 925 (62nd JECFA); Comments from Australia (CX/RVDF 04/15/4A, Add.1).
Quality of Data

23. In addition to detailed considerations and guidance at many previous meetings on data requirements and data quality, JECFA clarified that if it is unable to establish clearly that a study was conducted in accordance with recognized quality standards and protocols, it may decide to not consider this study and state the reasons clearly in the report.

Considerations on Marker Residues

24. The 60th JECFA affirmed its policy that the marker residue is a single compound (except stereoisomers), where the concentration decreases in a known relationship to total residues in tissues, eggs and milk. This applies to residues of toxicological and microbiological concern. For enforcement purpose, JECFA stressed the importance of having a single compound residue marker on which the MRLs are based.

Carbadox

25. Carbadox was first evaluated by JECFA at its 36th meeting (1991), but an ADI could not be established because of evidence of genotoxicity and carcinogenicity of carbadox and its metabolites desoxycarbadox and hydrazine. Based on the new data available, the 60th JECFA concluded that carcinogenic residues are present in edible tissues and that the actual amount of these residues cannot be determined with certainty from the length of the study provided. Therefore, JECFA could no longer support the MRLs proposed at its 36th meeting and recommended the withdrawal of the MRLs.

26. The recommendation of the 60th JECFA was supported by many delegations. However, the Delegation of the United States recommended that any action be deferred until several risk assessment activities of FAO, WHO and Codex Committees are completed. Because of the potential negative impact of these decisions on trade and animal health, the Delegation of the United States recommended that the current MRLs for carbadox remain in place at this time.

27. The CCRVDF agreed with the recommendation of the 60th JECFA and requested the 28th Session of the Commission to withdraw the MRLs for carbadox, which were adopted by the 20th Session of Commission.

Report of the 62nd JECFA Meeting

28. The 62nd JECFA considered eleven veterinary drugs: five antimicrobial agents (cefuroxime, chloramphenicol, flumequine, lincomycin and pirlimycin), four insecticides (cyhalothrin, cypermethrin/α-cypermethrin, doramectin and phoxim) and two production aids (melengestrol acetate and ractopamine). The Committee evaluated the safety of low levels of the antimicrobial agent chloramphenicol in animal products, and commented on the possible sources for low levels of chloramphenicol in food. In addition the Committee elaborated on a number of general principles.

29. Some delegations expressed concern, following similar concern raised at the previous Session that the close scheduling of JECFA and CCRVDF meetings resulted in the report of the latest JECFA meeting not being available, therefore not permitting adequate consideration of JECFA recommendations.

Conclusions on specific toxicological end-points

30. In an effort to improve consistency and transparency, the 62nd JECFA recommended elaborating a series of standard statements that allow clear and consistent conclusions for specific toxicological end-points, in particular on genotoxic and carcinogenic potential, as well as reproductive toxicity.
Lipid-soluble residues of veterinary drugs with MRLs in milk

31. Currently JECFA recommends MRLs on a whole milk basis based on the following reasons: “The potential effect of reporting an MRL on the basis of milk fat is demonstrated by the example of a substance that has an MRL of 1 mg/kg in whole milk. If fresh milk is composed of 4% milk fat, the MRL in milk fat would be 25 mg/kg (1mg/kg ÷ 0.04 = 25 mg/kg), assuming all residue partitions into the milk fat. In situations where milk or milk fat is used to produce commodities such as butter and cheese, the finished product may contain a very high percentage of milk fat, and thus very large amounts of residues. These highly elevated amounts of residues in the finished, processed product may exceed an amount that might pose public health concerns, for example, that could result in amounts of residues that may exhibit a toxic effect in humans. Such a determination would have to be considered on a case-by-case basis.”

32. Reporting an MRL of a lipid-soluble compound in milk on a milk fat basis would make it more consistent with JMPR procedures, thereby permitting the establishment of a single MRL for a substance, regardless of its origin as a veterinary drug or as a pesticide.

33. The CCRVDF recommended that JECFA and JMPR discuss the matter with the view of harmonizing their approaches to proposing milk MRLs for lipid soluble compounds and consider MRLs for milk both on fat and whole milk basis and report back at its next Session. The Committee confirmed that MRLs would continue to apply to milk as a whole product.

Statistical methods for the estimation of MRLs

34. For several previous meetings JECFA has used a statistical approach for the estimation of MRLs, e.g. for eprinomectin and dicyclanil.

35. This statistical approach included linear regression analysis of data describing the terminal depletion of a suitable marker residue and subsequent use of the results of the regression analysis for the estimation of statistical tolerance limits.

36. The 62nd JECFA welcomed the initiative of its Secretariat to make available a spreadsheet-based tool, which facilitates the calculations of MRLs, and recommended to further improve the current application; to extend its applicability and to publish the tool inviting all interested parties to comment on it; and to test and validate the tool.

37. With regard to this initiative, the CCRVDF encouraged the publication of the spreadsheet for statistical methods in deriving MRLs for reasons of transparency and public input.

Terminology for analytical methods (from the Codex Committee on Methods of Analysis and Sampling)

38. The 62nd JECFA considered a document on proposed revised definitions of analytical terminology contained in the Codex Procedural Manual prepared by the Codex Committee on Methods of Analysis and Sampling (CL 2003/43-MAS) and agreed in principle that definitions of analytical terminology used in JECFA documents should be harmonized with Codex definitions. Since work is still in progress in the Codex Committees, the 62nd JECFA agreed that this matter should be considered at its next meeting.

Comments on Chloramphenicol found at low levels in food

39. Based on evidence of genotoxicity in vivo, and epidemiological studies in humans which show that treatment with chloramphenicol is associated with the induction of aplastic anaemia, a rare disease which may be fatal and because it was not possible to establish any dose–response relationship or threshold dose, JECFA concluded that it was not appropriate to establish an ADI (acceptable daily intake) for chloramphenicol at that time.

40. Regarding the low concentrations of chloramphenicol found in foods, the Committee considered several scenarios, other than direct application of the compound, which could possibly lead to low level food contamination. Based on these considerations the 62nd JECFA concluded that:

- There was no evidence supporting the hypothesis that chloramphenicol is synthesized naturally in detectable amounts in soil. Although the possibility of such natural production is highly unlikely, data generated with modern analytical methods would be required to confirm this;

---

WHO TRS 925 (62nd Report of the JECFA, p. 3)
- There was evidence that the low concentrations of chloramphenicol detected by food monitoring programmes in the year 2002 could not originate from residues of chloramphenicol persisting in the environment after historical veterinary uses of the drug in food-producing animals. Owing to the high variability in the half-life of chloramphenicol under different environmental conditions, however, such a mechanism might occasionally cause low-level contamination in food.

REPORT OF THE OIE ACTIVITIES, INCLUDING THE HARMONIZATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF VETERINARY MEDICINAL PRODUCTS (VICH) (Agenda Item 5)\(^5\)

41. The need to strengthen cooperation between the Codex Alimentarius and OIE was highlighted as part of the objective aimed at protecting public health and facilitating world trade. The Representative of OIE stressed the need to make every effort to produce synergies and avoid any redundancy or gaps in the development of international standards pertaining to food safety. Strengthening cooperation agreements between the WHO, FAO and OIE, which was addressed during the last Codex Commission, would help address these issues and would minimise duplication of effort and the wasting of resources.

42. A review has been carried out on the activities of the OIE working group that handles food safety from animal production to slaughter, or to the first stage of food manufacture.

43. The work carried out as part of the VICH (International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products) was presented and progress made since the last session of the CCRVDF highlighted. The Representative of the OIE recommended that JECFA take into account relevant international standards within its area of expertise.

44. The Committee was advised that the strategic deliberations, led by the Steering Committee of the VICH under the auspices of the OIE with a view to defining the strategy for 2006-2010, will be presented at the VICH 3 Public Conference to be held in Washington on May 26 and 27, 2005. The OIE Representative stressed the VICH’s role in terms of harmonizing veterinary drugs registration and consequently protecting the food chain, hence the need to encourage wider acceptance of the VICH principles.

45. The issue of antimicrobial resistance was discussed and the Committee was reminded of OIE’s activities in this area since 1997. Five guidelines were adopted during the 71st and 72nd General Sessions of the OIE in 2003 and 2004. These guidelines, including the one relating to the responsible and prudent use of antimicrobial agents in veterinary medicine, have now become international standards and are used as a benchmark under the SPS agreements of the World Trade Organization. These guidelines may be obtained from the OIE or viewed on the OIE website\(^6\).

46. Because of the importance of this issue, it was highlighted the need to pursue work swiftly and in cooperation with all the other relevant organizations at world-wide level.

47. In that respect, the tripartite WHO/FAO/OIE Workshop held in Geneva in December 2003 and in Oslo in February 2004 specified the urgent work to be carried out, and recommended some practical cooperation arrangements to ensure the efficiency of work and to avoid any wasting of resources.

48. The recommendations of that consultation have been endorsed by the OIE, which would like to see stronger coordination and cooperation with the Codex Alimentarius. The OIE will follow with interest the ongoing Codex consultation with regard to the role the latter should play in terms of antimicrobial resistance and the work methods to be implemented.

49. The Representative of the OIE indicated that it is co-ordinating work with the FAO and the WHO in order to promptly implement the recommendations of the 2004 Oslo Workshop.

\(^5\) CX/RVDF 04/15/3; CX/RVDF 04/15/3, Add.1

\(^6\) www.oie.int
50. The Committee considered Agenda Items 6 (a) and 6 (b) as follows:

**Phoxim**

51. The Committee recalled that the 26th Session of the Commission had returned the draft temporary MRLs for phoxim in cattle tissues and cow’s milk to Step 6 pending JECFA re-evaluation.\(^8\)

52. The 62nd JECFA recommended withdrawing the temporary MRLs, as no new data had been provided for evaluation.

53. The Committee agreed with the recommendation of JECFA and discontinued work on the elaboration of MRLs for phoxim in cattle tissues and cows’ milk.

**Cyhalothrin**

54. The Committee recalled that the 26th Session of the Commission had advanced the proposed draft temporary MRLs for cyhalothrin to Step 6 only, pending further consideration by JECFA\(^9\).

55. The 62nd JECFA removed the temporary designation of the ADI and established an ADI of 0-5 µg/kg bw and confirmed all MRLs with the exception of the MRL in sheep liver, which was changed to 50 µg/kg.

56. The Committee, in noting that a validated method for the determination of MRLs for cyhalothrin was available, advanced to Step 8 the MRLs for cyhalothrin as recommended by the 62nd JECFA.

**Cefuroxime**

57. The Committee noted that the 26th Session of the Commission adopted at Step 5 and advanced to Step 6 the proposed draft temporary MRL for cefuroxime in cows’ milk\(^10\).

58. At its 58th meeting JECFA established a temporary ADI and a temporary MRL for cows’ milk and requested additional information on residues in milk. For the 62nd JECFA no new data were provided and therefore JECFA recommended withdrawing the temporary ADI and the temporary MRL.

59. The Committee agreed with the recommendation of the 62nd JECFA and discontinued work on the MRL for cefuroxime in cows’ milk.

**Draft MRLs retained at Step 6 by the 14th Session of the Committee**

60. The Committee recalled that at its 14th Session it had retained at Step 6 MRLs for melengestrol acetate, flumequine, neomycin, dicyclanil and trichlorfon (metrifonate), which were reconsidered by the 60th JECFA.\(^11\)

---

\(^7\) ALINORM 03/31, Appendix IV and V; ALINORM 03/31A, Appendix VI. Comments in response to CL 2003/24-RVDF submitted by European Community; Venezuela (CX/RVDF 04/15/4) and United States (CX/RVDF 04/15/4, Add.1). Comments on recommendations of the 60th and 62nd JECFA meetings submitted by Argentina, Canada, Egypt, United States, IFAH (CX/RVDF 04/15/4A), Australia, European Community, Malaysia (CX/RVDF 04/15/4A, Add.1), IFAH (CRD 6), Uruguay (CRD 9), India (CRD 10), IFAH (CRD 12).

\(^8\) ALINORM 03/41, para. 112.

\(^9\) ALINORM 03/41, para 116.

\(^10\) ALINORM 03/41, para 136.

\(^11\) ALINORM 03/31A, para. 63.
Melengestrol acetate

61. The JECFA Secretariat informed the Committee, that during the editing of the monograph for MGA, an inaccuracy in the calculation of the TMDI was detected. Therefore, the Secretariat suggested to the Committee that the TMDI and proposed MRLs should be re-assessed. A proposal by the Observer of IFAH for correcting the inaccuracy of the MRLs in fat and liver was not considered.

62. The Committee noted that the recalculated MRL for melengestrol acetate would be circulated for comments at Step 6 for consideration at its 16th Session.

Flumequine

63. The 60th JECFA withdrew the ADI established at its 48th meeting due to new data raising toxicological concern and recommended the withdrawal of MRLs for all species. At the 62nd JECFA additional data were provided that addressed the concern raised at the 60th meeting and as a consequence JECFA re-established the ADI and the previous MRLs and recommended a new temporary MRL for black tiger shrimp.

64. The Committee noted that the JECFA had proposed a temporary MRL for flumequine in black tiger shrimp as data submitted were only for that species of shrimp. It further noted that although the issue of extrapolation from species to species had been considered several times, a policy had not yet been agreed on this matter. Several delegations suggested that the Committee should consider widening the scope of the MRL for the substance to all shrimp species.

65. The Committee advanced all draft MRLs for flumequine to Step 8 with the exception of the proposed draft temporary MRL in black tiger shrimp, which was advanced to Step 5 for adoption by the 28th Session of the Commission.

Neomycin

66. The 60th JECFA decided to revert to the MRLs for cattle kidney and liver that it recommended at its 47th meeting and recommended the MRLs for cattle kidney and liver and cows’ milk. MRLs for cattle muscle and fat and all other MRLs were maintained.

67. The Committee advanced the MRLs for neomycin as proposed by the 60th JECFA to Step 8.

Dicyclanil

68. The 60th JECFA recommended new MRLs for sheep tissue (muscle, liver, kidney and fat).

69. The Committee advanced the MRLs for dicyclanil, as proposed by the 60th JECFA, to Step 8.

Trichlorfon (metrifonate)

70. The 60th JECFA re-evaluated the ADI based on new data and established a new ADI of 0-2 µg/kg body weight. JECFA confirmed the proposed MRLs for cows’ milk and the guidance level for muscle, liver, kidney and fat of cattle, which is based on the limit of quantification of the analytical method (50 µg/kg).

71. The Delegation of the European Community stated that they could not accept the recommendations of the 60th JECFA due to the clear evidence of mutagenicity both in vivo and in vitro. It was further stated that there was no evidence of a NOEL for these effects and no new information suggesting that these data were not valid. In addition, it was noted that other reasons for not accepting the ADI and marker residue for trichlorfon (m trifonate) included: the inappropriate end point used for determining the ADI; the absence of a clear NOEL for developmental toxicity and for the two-generation reproductive study; the evidence of delayed neurotoxicity; the lack of an ADI for dichlorvos (active metabolite); and the marker residue identified by JECFA. These comments were supported by a number of delegations.

72. The Observer from Consumers International informed the Committee of a study on the developmental neurotoxicity of trichlorfon recently submitted to the US Environmental Protection Agency (EPA).

73. Other delegations were of the opinion that all concerns raised by the European Community had been adequately addressed by the 60th JECFA. It was also pointed out that trichlorfon had been in use for many years and that JECFA had a large collection of data for the evaluation.
74. Due to the different opinions in terms of the scientific conclusions reached by JECFA for the
determination of the ADI, the Committee agreed to hold the MRLs for trichlorfon at Step 7 pending the
submission of new data for JECFA re-evaluation. In addition, the Committee requested the Delegation of the
European Community to liaise with the JECFA Secretariat to verify the nature of the data used for their
evaluation and to submit in writing their concerns. The JECFA Secretariat agreed to reschedule trichlorfon as
a priority substance and to specifically address the concerns raised by the Delegation of the European
Community (see Agenda Item 12).

Proposed draft MRLs at Step 3

75. The Committee noted that the 26th Session of the Commission adopted the priority list of veterinary
drugs requiring evaluation or re-evaluation proposed at its 14th Session as new work for the Committee.12

Imidocarb

76. The 60th JECFA recommended new MRLs for edible cattle tissue (muscle, kidney, liver, fat and cow’s
milk).

77. The Committee advanced the MRLs for imidocarb to Step 5 and 8, with the omission of Step 6 and 7,
and recommended withdrawing the temporary MRLs, which were adopted by the 24th Session of the
Commission.

Pirlimycin

78. This compound had not been previously evaluated by JECFA and the 62nd JECFA established an ADI
of 0-8 µg/kg body weight. MRLs were recommended for pirlimycin in cattle (liver, kidney, muscle and fat)
and cows’ milk.

79. The Committee supported the tissue MRLs for pirlimycin. With regard to the MRL for cows’ milk, the
Observer from IFAH noted that it was based on the potential inhibition of dairy starter culture and
considered this criterion inappropriate as a basis for an international standard, which should be based on
safety consideration only. Moreover, it was observed that the proposed MRL would result in long withdrawal
time leading to the discard of a considerable amount of milk. Therefore, it was requested that the milk MRL
for pirlimycin be re-evaluated by JECFA on the basis of food safety consideration only.

80. The Committee noted that the decision to calculate MRLs on the basis of food safety or food
processing technological consideration was a risk management policy decision. It further noted that the
JECFA report contained both a toxicological and microbiological ADI and criteria for the selection that
would have allowed the Committee to recalculate the MRLs on the basis of their policy decision. A re-
evaluation by JECFA would not be required.

81. The Committee advanced all MRLs for pirlimycin to Step 5 and noted that Members and observers
would have the possibility to provide further comments at Step 5 and 6 regarding the criterion to be used for
the calculation of the MRLs for milk.

Cypermethrin/alpha-cypermethrin

82. The 62nd JECFA re-evaluated cypermethrin and alpha-cypermethrin with the aim of setting a common
ADI and MRLs. JECFA noted that both compounds are qualitatively similar with regard to toxicity and
metabolism, that they frequently occur together and that alpha-cypermethrin is toxicologically more potent.
Based on these considerations JECFA established a group ADI for cypermethrin and alpha-cypermethrin
based on the previously established ADI for alpha-cypermethrin. New MRLs were recommended based on a
new residue definition of total cypermethrin residues for cattle and sheep fat, cattle and sheep kidney, liver
and muscle and sheep and cows’ milk.

83. The Committee advanced the group MRLs for cypermethrin/alpha cypermethrin to Step 5 and agreed
to discontinue work on the elaboration of separate MRLs for the two substances.

---

12 ALINORM 03/41, para 138 and Appendix VIII.
Doramectin

At the request of the 14th CCRVDF, the 62nd JECFA recommended a new MRL for cows’ milk, but noted that the necessary discard times are very long and unlikely to be consistent with good veterinary practice.

A number of delegations shared the concern of JECFA that the long discard periods might not be complied with in practice, leading to concerns about consumers’ safety and supported the inclusion of the footnote mentioning the long discard times in the JECFA report. In this regard it was noted that it contributed to make the process of establishing the MRL more transparent.

Other delegations, while supporting the MRL recommended by the 62nd JECFA, questioned the purpose and the accuracy of the footnote. In this regard it was also noted that the good veterinary practices and withdrawal times were within the purview of national authorities and that the footnote did not apply globally as Good Veterinary Practices (GVPs) the methodology for calculating the withdrawal period varied among regions. It was also noted that the footnote proposed by JECFA could raise concern for food safety and might give grounds to countries to deny product authorizations.

The Committee advanced the MRL for doramectin in cows’ milk (including the footnote) to Step 5. With regard to this decision, the Delegation of the European Community stated that although it was not in favour of establishing a MRL for doramectin in milk, it could accept the MRL provided the footnote was included.

Ractopamine

The 62nd JECFA re-evaluated ractopamine and established an ADI of 0-1 µg/kg body weight. New MRLs were recommended for edible tissues of pigs and cattle (muscle, liver, kidney and fat). The JECFA Secretariat noted that the questions raised at the previous JECFA evaluation of this compound could all be addressed based on the data available for the evaluation at the 62nd meeting.

The Delegation of the European Community, supported by other delegations, stated that they could not support the advancement of the MRLs for ractopamine as they had not sufficient time to consider in detail the report of the 62nd JECFA due its late distribution. It was noted that ractopamine has not been evaluated within the European Community and that a number of questions had been raised on the safety of the substance at the previous JECFA evaluation.

In noting that all toxicological concerns raised by the 40th JECFA, had been adequately addressed by the 62nd JECFA, the Delegation of the United States supported by other delegations, was in favour of advancing the MRLs for ractopamine. The Delegation also observed that the MRLs proposed by JECFA had a wide margin of safety and were significantly lower than those in the United States, and in other countries, partly due to the effect of rounding the ADI and urged JECFA to recalculate the tolerances.

In view of the lack of consensus, the Committee retained the MRLs for ractopamine at Step 4, with the understanding that, after detailed examination of the report of the 62nd JECFA, due consideration would be given to the advancement of the MRLs to Steps 5 and 8 at its next Session.

Status of the Draft and Proposed Draft Maximum Residue Limits for Veterinary Drugs

Draft MRLs advanced at Step 8 and proposed draft MRLs advanced to Steps 5/8 (with the omission of Steps 6 and 7) for final adoption by the 28th Session of the Commission are attached as Appendix II and III. Proposed draft MRLs advanced for adoption at Step 5 are attached at Appendix V. Proposed draft MRLs retained at Step 7 and Step 4 are attached at Appendix IV and VI, respectively.

The Committee agreed to inform the Commission of the discontinuation of work on: MRLs for phoxim in cattle tissues and cows’ milk; MRL for cefuroxime in cows’ milk; and separate MRLs for cypermethrin and alpha-cypermethrin (see Appendix VII).
94. The Committee recalled that at its 14th Session, it had decided to request additional comments on document CX/RVDF 03/6 “Proposed draft Code of Practice to Minimize and Contain Antimicrobial Resistance” and that a working group would prepare a revised version of the proposed draft Code of Practice by the end of 2003 for circulation, comments and further consideration at its 15th Session.14

95. The Committee was informed that a Working Group, which met before the Session, considered the comments submitted on the proposed draft Code of Practice, in order to facilitate the discussion during the Session. The Committee agreed to consider the report of the Working Group (CRD 14) as the basis for its discussion.

96. The Chairperson of the Working Group informed the Committee that the Working Group took account of the decision of the 27th Session of the Commission regarding antimicrobial resistance15 and considered three options: i) stop the work in the Committee and request the OIE to continue the development of the Code; ii) accelerate the completion of the Code in order to minimize gaps and inconsistencies with OIE relevant texts; iii) prepare a further draft for future consideration of the Committee. The Working Group decided that the second option was the most suitable one and this was agreed by the Committee.

97. The Representative of the OIE congratulated the Working Group for the quality of the document and the progress achieved, however he expressed concern as to the future development of the document. The Representative of the OIE recalled that there were already five OIE international guidelines, which are references on this subject within the WTO framework. The problem was related to the implication of the co-existence of two texts dealing with the same subject which are not exactly identical. The Representative of the OIE stressed that a possible solution within Codex could be to adopt by “reference” the OIE Guidelines on the prudent and responsible use of antimicrobials in veterinary medicine and that the OIE could take into account the comments of the Codex Working Group to improve the text.

98. The need to improve harmonisation among international organizations was recognised by the Committee.

General Comments

99. The Working Group in considering the terminology used in the Glossary annexed to the Code, agreed to refer to “Veterinary Antimicrobial Drugs” because it was more appropriate to the Code and the term “Veterinary Drug” is already defined in the Procedural Manual of the Codex Alimentarius. However, concern by the Delegation of the United States and some others was expressed as to the inclusion of anticoccidials in this definition. In addition, the Working Group also deleted throughout the Code references to “drugs of significance to human health” and similar terms because they were not defined and agreed to refer to risk analysis instead of risk-based or risk-benefit because the definition of risk analysis allows for a more comprehensive approach.

100. The Committee considered the issue of the inclusion of anticoccidials in the definition of “Veterinary Antimicrobial Drugs” and recognised the difficulty of trying to draw a clear separation between anticoccidial and antimicrobial drugs. It was also noted that in some cases the definitions of anticoccidials were different in the legislation of some countries. While some delegations were in favour of their inclusion in the definition, others objected to it because of the potential difficulties that this might cause in international trade and the difficulties that some countries might have in enforcing this requirement.

13 CL 2003/40-RVDF; Comments submitted by Canada, Colombia, Ecuador, Egypt, Japan, Malaysia, CI, IFAH, OIE (CX/RVDF 04/15/5); Cuba, United States (CX/RVDF 04/15/5, Add.1), European Community (CRD 7) and Norway (CRD8). Report of Working Group on the proposed draft Code of Practice to Minimize and Contain Antimicrobial Resistance (CRD 14).
14 ALINORM 03/31A, para. 79.
15 ALINORM 04/27/41, paras 210-219.
101. The Committee considered several options and finally agreed to the compromise definition below:

*Veterinary Antimicrobial Drug*

*Veterinary Antimicrobial Drug* refers to a naturally occurring, semi-synthetic or synthetic substance that exhibits antimicrobial activity (kills or inhibits the growth of microorganisms). Where anticoccidial products have antibacterial activity, they should be considered as veterinary antimicrobial drugs, except where this is precluded by national legislation.

102. The Committee agreed with the conclusions of the Working Group: i) to delete all references to veterinary antimicrobial drugs of critical importance to human medicine or similar terms throughout the text pending a definition of what is important for human health; and ii) to refer to risk analysis only. In noting that the terms “antimicrobials”, “antimicrobials agents”, “veterinary antimicrobials” and similar terms were used inconsistently throughout the text, the Committee agreed to refer to “veterinary antimicrobials drugs” only.

**Specific Comments**

103. The Committee considered the proposed draft Code in detail and, in addition to the above changes and minor editorial changes, including amendments to the French and Spanish translations, agreed to the following changes:

**Aims and Objectives**

104. The Committee amended the last bullet in paragraph 6 to read “comply with the ethical obligation and economic need to maintain animal health” for clarity. The first sentence in paragraph 7 was deleted as inappropriate.

**Responsibilities of the Regulatory Authorities**

105. In the first sentence of paragraph 9 it was added “and or by other means” after “through the product labelling” to recognize that appropriate information is also provided by other means, such as codes of practices. In the first bullet of paragraph 11, the verb “must” was changed with “should” for consistency with the rest of the text. The Committee amended the first sentence of paragraph 16 to emphasize that countries should make every effort to actively combat the advertising of illegal or counterfeit bulk active pharmaceutical products.

106. The Committee recognised the importance of the legality of use of veterinary antimicrobial drugs and added in the last sentence of paragraph 16 “or when feasible, certificates of compliance with Good Manufacturing Practices (GMPs)” to allow a certain flexibility in the application of this requirement in the interest of all parties.

**Assessment of Efficacy**

107. In the second sentence of paragraph 18, the Committee added “where applicable”, with reference to conducting pharmacokinetic and pharmacodynamic studies for the assessment of efficacy, to recognise that there could be situations where the results of these studies cannot be used.

**Assessment of the potential of veterinary antimicrobial drugs to select for resistant microorganims**

108. The first bullet of paragraph 25 was deleted as redundant with the second bullet. In the last bullet “enabling the derivation of microbiological ADI” was deleted as incorrect.

**Establishment of ADIs (acceptable daily intake), MRLs (maximum residue limit), and withdrawal periods for veterinary antimicrobial drugs**

109. In paragraph 26, “(e.g., the potential biological effects on the human intestinal flora)” was moved to after “the determination of microbiological” for clarity. In paragraph 27, “fish” was included among the examples of appropriate foodstuff for which MRLs should be established. The paragraph was also amended to refer to “recognised control laboratories” as the legal implication of the term “approved”.
**Surveillance Programmes**

110. The Committee clarified that the documents listed in the indent of paragraph 31 were an example of international texts on the harmonisation of monitoring and surveillance programmes. In the third bullet, the term “wholesale and retail” was added as data sources on usage and for consistency with other sections of the Code, e.g. Section entitled “Responsibilities of Wholesale and Retail Distributors and “pharmacists” deleted as this was included in with wholesalers.

**Distribution of veterinary antimicrobial drugs in veterinary medicine**

111. In paragraph 34, the first bullet was aligned with the language of paragraph 13 by adding “or used under conditions stipulated in the national legislation”; and the second bullet was deleted.

**Training of the users of veterinary antimicrobial drugs**

112. The title of the section was amended to read “Training of the users of veterinary antimicrobial drugs” for clarity. In paragraph 36 “and other approved users such as farmers and producers of food producing animals” was added for consistency with paragraph 31.

**Responsibilities of Wholesale and Retail Distributors**

113. Paragraph 45 was amended to clarify the role of distributors in encouraging compliance with national guidelines.

**Responsibilities of Veterinarians**

114. The Committee deleted the second part of paragraph 49, as it was considered too detailed. The Committee recognised that in the preventive use of veterinary antimicrobial drugs it was not realistic to carry out sophisticated types of investigation/diagnosis, therefore it amended the second bullet of paragraph 50 as follows “All antimicrobial veterinary drugs should be prescribed and used according to the conditions stipulated in the national legislation”.

115. In paragraph 56 it was clarified that the scope of the periodical review of farm records on antimicrobial use was to ensure compliance with the directions given by the veterinarians.

**Responsibilities of Producers**

116. The Committee added to the fourth bullet of paragraph 59 “under conditions approved by relevant authorities” for clarity.

**Status of the proposed draft Code of Practice to Minimise and Contain Antimicrobial Resistance**

117. The Committee agreed to advance the proposed draft Code of Practice to Steps 5/8, with the omission of Steps 6 and 7, for adoption by the 28th Session of the Commission (see Appendix VIII).

**PROPOSED DRAFT REVISED GUIDELINES FOR THE ESTABLISHMENT OF A REGULATORY PROGRAMME FOR THE CONTROL OF VETERINARY DRUG RESIDUES IN FOODS (INCLUDING APPENDIX ON THE PREVENTION AND CONTROL OF VETERINARY DRUG RESIDUES IN MILK AND MILK PRODUCTS) (Agenda Item 8)**

118. The Committee recalled that at its last Session, it was decided to request comments on document CX/RVDF 03/7 and that a working group, led by New Zealand, would prepare a revised version of the guidelines, including the proposed draft Appendix on the control of veterinary drugs residues in milk and milk products, for circulation, comments and further consideration at the current Session.17

---

16 CX/RVDF 04/15/7; Comments submitted by Australia, European Community; United States; CI, IDF (CX/RVDF 04/15/7, Add. 1), Canada (CRD 5), Uruguay (CRD 9) and India (CRD 10).

17 ALINORM 03/31A, para. xx
119. The Chair of the Working Group noted that few comments had been received in response to the Circular Letter and that the specific issues on milk had been harmonised and included in the document. The Delegation noted that the comments submitted at the present Session focused on the need to restrict the monitoring to residues of veterinary drugs and to delete any reference to the control of pesticide and other contaminants and that the majority of comments could be easily incorporated in a further draft of the document. It was also stated that nothing in the document was intended to preclude national authorities from taking appropriate regulatory actions against residues in excess of the MRLs.

120. The Committee expressed appreciation for the work done and agreed with the general approach of the revised document. It was noted by some delegations, highlighted both in the discussion and in their written comments, that: some additional work was needed to strengthen some aspects of the document; the scope should not address the issue of antimicrobial resistance as this was covered by other texts; the document should address the need of developing countries for a gradual implementation of the control measures; the document should clearly distinguish between legal and illegal use; the document should demonstrate more clearly and in more detail how the HACCP system should be applied to a residue control programme; that more emphasis should be given on providing feedback to optimise regulatory systems than to statistical relevance of non-biased sample taking; and that attention be given to the problem of acute single exposure. The Delegation of the European Community and the Observer of Consumer International were of the opinion that the document should not imply that exceeding an MRL is a matter of little significance.

121. With regard to the Joint FAO/WHO Technical Workshop, the Committee suggested addressing the recommendation regarding the evaluation of food consignments containing residues of veterinary drugs which should not be used in food producing animals, and the control of residues in the entitled Section “Port of entry testing programmes”.

122. The Delegation of New Zealand noted that these were very new and potentially contentious areas that could significantly delay the progress of the Guidelines and suggested that a new Working Group would be more appropriate. The Committee did not agree to the formation of a new Working Group, as proposed by the Delegation of New Zealand. The Delegation of New Zealand agreed to absorb this task into the next revision, but expressed concern that this may be difficult to achieve and could delay progress. The Committee accepted these concerns but expressed the wish that the inclusion of this matter into the main document would not delay work on the main document, noting that a separate document on this recommendation might be developed in the future, if required.

Status of the proposed draft Revised Guidelines for the Establishment of a Regulatory Program for the Control of Veterinary Drug Residues in Foods

123. The Committee returned the proposed draft revision of the Guidelines to Step 2 for redrafting by a Working Group led by New Zealand. It agreed that the Working Group would prepare a revised version of the Guidelines, based on the written comments submitted at the current Session and the above discussion, by September 2005 for circulation, comments and consideration at its 16th Session.

PROPOSED DRAFT REVISED PART II “GENERAL CONSIDERATIONS ON ANALYTICAL METHODS FOR RESIDUE CONTROL” OF THE CODEX GUIDELINES FOR THE ESTABLISHMENT OF A REGULATORY PROGRAMME FOR THE CONTROL OF VETERINARY DRUGS RESIDUES IN FOODS (Agenda Item 9)

124. The Co-Chair of the ad hoc Working Group on Methods of Analysis and Sampling, Dr James MacNeil (Canada), presented the report of the Working Group, held prior to the session that had addressed the revision of the working document among other issues.
125. The Working Group had expressed general support for the document and agreed that the recommendations resulting from the Joint FAO/WHO Technical Workshop on Residues of Veterinary Drugs without ADI/MRL related to methods of analysis and laboratories, could be addressed in the revision of Part II and III of the *Guidelines for the Establishment of a Regulatory Programme for the Control of Residue of Veterinary Drugs in Foods*. The Working Group had also discussed a suggestion to review Part I of the Guidelines concerning sampling, that would require additional expertise concerning statistics and sampling.

126. The Committee noted that the recent revision of analytical terminology and the adoption of criteria for single laboratory validation developed by the Committee on Methods of Analysis and Sampling, as well as the work of the Committee on Pesticide Residues in that area, would be taken into account in further work on the document.

127. The Delegation of the European Community expressed the view that the document was too long and should be redrafted in order to be more easily understandable for regulatory authorities. The Delegation of Thailand stressed the importance of addressing the issues related to methods of analysis and sampling identified by the Joint FAO/WHO Technical Workshop on Residues of Veterinary Drugs without ADI/MRL in order to ensure consumers’ health protection and to avoid trade barriers.

128. As regards the recommendations of the Technical Workshop concerning the networking of laboratories, the Representative of FAO indicated that technical cooperation activities had been developed to facilitate regional cooperation between laboratories and that its extension to analysis of veterinary drugs residues could be considered. The Delegation of the Netherlands advised the Committee of an existing European network of residue testing laboratories. The Representative of IAEA also informed the Committee about the cooperation activities of the Joint FAO/IAEA Division in the area of residue analysis.

129. The Committee agreed to proceed with the revision of the Guidelines CAC/GL 16-1993, Part II and to expand this work to include Part III: Attributes of Analytical Methods for Residues of Veterinary Drugs, and Part I on Sampling, as appropriate, in conjunction with the Working Group on the revision of the Guidelines, chaired by New Zealand (see Agenda Item 8). The Committee agreed that the recommendations of the Technical Workshop concerning analytical methods should be addressed in the process; this would include the recommendation of criteria for methods applied to the detection, determination or confirmation of residues of non-approved drugs.

130. The Committee noted that the revision of some terms in the Glossary or of the entire Glossary might be required as a result of the revision, and agreed that the decision to revise a part of or the whole Glossary could be taken at the next session, if required. The Secretariat indicated that the revision of all analytical terminology in the Procedural Manual was underway in the CCMAS and invited interested delegations to provide their comments and proposals to that Committee, as analytical terms of general relevance could be included in the Procedural Manual.

131. The Working Group also commended the Delegation of the United Kingdom for making available increased amounts of tissues containing residues and expressed the hope that this initiative would be continued and expanded.

**Status of Part II of the proposed draft revised Guidelines for the Establishment of a Regulatory Programme for the Control of Residue of Veterinary Drugs in Foods**

132. The Committee agreed to return the Proposed Draft Revised Guidelines to Step 2, and agreed that the Delegation of Canada, with the assistance of a Working Group20, would redraft all sections on methods of analysis and sampling in the *Guidelines* (Part I, II and III), for comments and consideration by the next session.

133. The Committee noted that the sections on methods of analysis and sampling would be revised concurrently with the main body of the Guidelines concerning regulatory programmes (see Agenda Item 8), and agreed that close coordination should be exercised between the relevant working groups.

---

20 Australia, Brazil, Korea, Netherlands, Poland, Sweden, United Kingdom, Thailand, United States
DISCUSSION PAPER ON RISK MANAGEMENT METHODOLOGIES, INCLUDING RISK ASSESSMENT POLICIES IN THE CODEX COMMITTEE ON RESIDUES OF VETERINARY DRUGS IN FOODS (Agenda Item 10)  

134. The Committee recalled that its last session had agreed that a drafting group led by the Delegation of France would prepare an internal policy document on risk management methodologies, including risk assessment policies, on the basis of the document presented at the 14th Session (CX/RVDF 01/9) and the comments to be provided by JECFA.

135. The Delegation of France introduced the revised document and indicated that it had been revised on the basis of the comments submitted to the 14th Session of the Committee and in accordance with the Working Principles for Risk Analysis in the Framework of the Codex Alimentarius. The Delegation indicated that some issues required further discussion, and in particular: risk communication; intellectual property rights; risk assessment policy; the question of veterinary drugs with a long history of use; and the criteria for priorities.

136. The Delegation of Japan expressed the view that the request of the Commission to Codex Committees related to risk analysis policies and that the Committee should develop a document on risk analysis and not exclusively on risk management.

137. The JECFA Secretariat indicated that the comments formulated by the 62nd JECFA on the earlier version of the document had been adequately taken into account in the current version.

138. Some delegations pointed out that continued interaction with JECFA would be necessary in the development of the paper. The Committee noted that the date of the next meeting of JECFA on veterinary drugs had not yet been set and that JECFA was not a permanent committee. It was therefore agreed that the JECFA Secretariat would participate in the further development of the document in the working group.

139. As regards the three definitions related to food safety objectives adopted by the 27th Session of the Commission, the Chair of the ad hoc Working Group noted that these definitions were not directly relevant in the framework of risk analysis of veterinary drugs residues. The Observer of IDF indicated that these new approaches, using Food Safety Objectives, Performance Objectives and Performance Criteria could provide helpful opportunities for risk management in some situations, for example where ADI/MRL had not been established.

140. The Committee had a discussion on the paragraphs that were highlighted in the working document and made the following comments.

**Parties involved**

141. The Committee had an extensive discussion on the need for communication strategies for risk analysis. Several delegations stressed the need for better communication between risk assessors and risk managers. The Observer from Consumers International expressed the view that communication with the public was an essential aspect of risk analysis in order to ensure public confidence in the process. The Delegation of the European Community expressed the view that the document should concentrate on communication between risk assessors and risk managers and that communication with the public might be better addressed by national governments.

142. The JECFA Secretariat highlighted the importance of adequate risk communication, especially if new procedures were developed for risk analysis of veterinary drugs, and in the case of substances that currently had no ADI or MRLs.

143. The Committee agreed that risk communication strategies should be further considered in the development of the document, and noted that the section on Risk Communication in the Working Principles for Risk Analysis in the Framework of the Codex Alimentarius could be taken into account in the process.

---

21 CX/RVDF 04/15/08, CX/RVDF 04/15/08-Add.1 (comments of Argentina, Canada, Denmark, United States)
144. In reply to a question on risk assessment procedures, the Representatives of FAO and WHO informed the Committee that the procedures of JECFA and JMPR were in the process of review and would be available upon completion of the Joint FAO/WHO Project to Update the Principles and Methods for the Risk Assessment of Chemicals in Foods, scheduled for 2005. It was noted that what constitute Good Veterinary Practices, as applied to milk withdrawal time, should be considered a component of the risk management process.

**Risk Management in the CCRVDF**

**Identification of a Food Safety Problem**

145. The Committee noted that to be consistent with the mandate of the Codex Alimentarius, food safety needs and public health concerns (paragraphs 11 and 13), trade issues of relevance for governments should also be identified.

146. The Committee noted the written comments of Argentina, which was not present at the meeting, concerning intellectual property in paragraph 12. In this respect, the Secretariat informed the Committee that the *Working Principles for Risk Analysis in the Framework of the Codex Alimentarius* (paragraph 6) addressed the issue of confidentiality as related to the accessibility of documentation.

147. Some delegations and the Observer from IFAH expressed the view that what constituted “documentation” for the purpose of risk analysis should be more clearly defined and that intellectual property issues should be further clarified.

148. The JECFA Secretariat recalled that procedures existed to ensure confidentiality of proprietary information in JECFA but that toxicological information was published in the report of the risk assessment.

149. The Committee agreed that a risk assessment policy should be established and the issue of “drugs with a long history of use” should be addressed, and noted that this was related to the establishment of lists of substances of interest to member governments that would be considered in the discussion on priorities (see also Agenda Item 12).

150. Regarding the provisions on the risk profile in paragraph 16, the JECFA Secretariat clarified that the qualitative risk profile should be provided by the delegation that initially proposed the substance for evaluation, in reply to the questionnaire sent to request comments on priorities.

**Monitoring and review of the decisions taken**

151. The Committee agreed that a list of veterinary drugs for which no ADI or MRL had been established should be compiled and discussed whether a policy should be established concerning the status of that list but did not come to a conclusion. Some delegations pointed out that the absence of a MRL did not directly relate to a food safety issue, as in some cases MRLs had not been established, due to insufficient data or lack of data for minor species. In reply to a question, the JECFA Secretariat indicated that a Summary of JECFA Evaluations of Veterinary Drugs Residues from the 32nd Meeting to the present (62nd Meeting) had been published in the document FAO FNP 41/16. This document also contains a list of compounds which have been evaluated by JECFA but for which an ADI and/or MRL was not recommended.

152. The Committee recalled the request of the Commission for Codex Committees to complete their work on guidelines on risk analysis in their respective areas and agreed that the discussion paper should be redrafted as a working document for inclusion in the Procedural Manual, with a view to its finalization at the next session. The Committee agreed that the document was being developed in response to a direct request of the Commission and did not need to go through the Step Procedure.

153. The Committee agreed that the document should be redrafted by the Delegation of France with the assistance of a working group\(^\text{22}\) taking into account the written comments, the discussion at the present session, and the recommendations of the Joint FAO/WHO Technical Workshop on Residues of Veterinary Drugs without ADI/MRL, where applicable. It requested the Working Group to submit the revised version by September 2005, for comments and consideration by the next session.

\(^{22}\) Australia, Burkina Faso, Brazil, Canada, China, Colombia, Costa Rica, European Community, Japan, Korea, Malaysia, Netherlands, Switzerland, Sweden, Thailand, United States, ALA, CI, IFAH, OIE, and OIRSA
The Committee expressed its appreciation to the Delegation of France and to the Working Group for their constructive work to address complex risk management issues.

METHODS OF ANALYSIS FOR RESIDUES OF VETERINARY DRUGS IN FOODS (Agenda Item 11)  

REVIEW OF PERFORMANCE-BASED CRITERIA FOR METHODS OF ANALYSIS FOR RESIDUES OF VETERINARY DRUGS IN FOODS (Agenda Item 11a)

155. Following its earlier decision concerning the revision of all provisions related to methods of analysis and sampling in the *Guidelines for the Establishment of a Regulatory Programme for the Control of Residue of Veterinary Drugs in Foods*, the Committee agreed that the document prepared for the 14th Session of the Committee (CX/RVDF 03/10) could be used as the resource document for the revision of Part II and Part III of the *Guidelines* (see Agenda Item 9) and agreed that there would be no more work on this document.

IDENTIFICATION OF ROUTINE METHODS OF ANALYSIS FOR VETERINARY DRUG RESIDUES IN FOODS (Agenda Item 11b)

156. The Committee noted that the *ad hoc* Working Group on Methods of Analysis and Sampling had considered a compilation of methods of analysis for veterinary drug residues previously recommended by the *ad hoc* Working Group and JECFA as suitable for support of MRLs. The list included fully validated methods; provisionally validated methods (single-laboratory validation only); and methods for substances without MRLs. A list of MRLs that are not supported by a suitable validated method had also been identified. The *ad hoc* Working Group agreed to update the list of methods regularly for each meeting of the Committee.

157. Some delegations proposed to retain the list of methods as an informal document that could be updated regularly for information purposes. The Codex Secretariat, however, recalled that the terms of reference of the Committee included the consideration of methods of analysis to determine the MRLs, and that MRLs had been included together with the corresponding methods in Volume 3, although no new methods had been identified in the most recent sessions. Methods of analysis should be adopted by the Commission for inclusion as methods intended for the determination of MRLs.

158. The Committee recognized that it had not been possible for governments to consider and comment on the list of methods presented at the session and that it was not possible to finalize a list of methods to be submitted to the Commission.

159. The Committee agreed that the list prepared for and recognized at the present session would be circulated for comments and the inclusion of additional methods and considered further at the next session, with a view to the finalization of suitable methods for adoption as Codex methods for the determination of veterinary drug residues.

160. The Committee expressed its appreciation to the *ad hoc* Working Group and to its co-chairs, Dr MacNeil (Canada) and Dr Stephany (Netherlands), for their comprehensive work to address important methodology issues, and agreed that the *ad hoc* Working Group on Methods of Analysis and Sampling should be re-convened prior to the next session.

161. Some delegations expressed their appreciation to the United States Secretariat for providing interpretation during the working group sessions.

---

23 CX/RVDF 03/10, CRD 1 (Report of the *ad hoc* Working Group on Methods of Analysis and Sampling)

24 CX/RVDF 04/10
CONSIDERATION OF THE PRIORITY LIST OF VETERINARY DRUGS REQUIRING EVALUATION OR RE-EVALUATION (Agenda Item 12) 25

162. The report of the *ad hoc* Working Group on Priorities that had met prior to the session was presented by its chair, Dr Lee Cook (Australia). The *ad hoc* Working Group had considered the proposals put forward for inclusion in the priority list and noted the commitment of Australia to provide data on triclabendazole; the proposals of Thailand for the evaluation of tylosin, erythromycin and enrofloxacin as the absence of Codex MRLs led to trade problems; the written proposal of Egypt to evaluate clindamycin; and the re-evaluation of melengesterol acetate proposed by JECFA.

163. The Committee noted that no information was available on the proposal of Egypt to evaluate clindamycin and therefore agreed that it should not be included in the list of priorities.

164. The JECFA Secretariat stressed the importance of providing the data requested for the evaluation of substances included in the priority list, and recalled that otherwise it would not be possible to schedule a JECFA meeting to consider these substances.

165. The Delegation of Thailand confirmed that it would provide the data for the evaluation of tylosin, erythromycin and enrofloxacin and that the uses proposed were allowed in its national legislation. For the three substances, the *ad hoc* Working Group noted that the dossiers had been submitted to the European Community and it was suggested that the EC might be able to send these dossiers to JECFA. In this regard, the Delegation of the European Community explained that the dossiers submitted remain the property of the sponsor and could not be submitted to JECFA without the sponsor’s permission.

166. The Observer from IFAH explained the concerns arising from its member companies for substances that are off-patent and are marketed in the world by many different companies and the additional concern that the publication of detailed monographs by JECFA might be used for registration of products from competitors. Furthermore, the identification of a sponsor company could be difficult in cases when special uses are not supported by the pioneer sponsor.

167. The Delegation of the United States proposed the re-evaluation of ractopamine in order to re-calculate the MRL, following earlier discussion on the rounding of the ADI (see Agenda Item 13a).

168. The Delegation of the European Community proposed that JECFA reconsider the ADI/MRLs for trichlorfon (metrifonate) (see Agenda Item 6).

169. The Delegation of the Republic of Korea proposed to include colistin in the priority list and indicated that it would provide microbiological studies on the effect on the intestinal flora of this substance. The Committee noted that the Delegation would have to consult with the JECFA Secretariat in order to clarify the data available and the questions to be answered in the evaluation.

170. The Committee noted that India had suggested in its written comments (CRD 10) the re-evaluation of pirlimycin for milk; cyhalothrin for milk; cypermethrin and alpha-cypermethrin for different cattle products; doramectin for all cattle products and not just for milk; and chloramphenicol and nitrofurans. However, because of the late submission, the Committee was not able to consider these requests for inclusion in the priority list.

171. The Committee agreed to include the above proposals in the list of priorities for evaluation or re-evaluation by JECFA. The Priority List of Veterinary Drugs Requiring Evaluation or Re-evaluation is attached as Appendix IX.

*Other matters related to priorities*

172. The Committee noted that the *ad hoc* Working Group had discussed the recommendations of the Joint FAO/WHO Technical Workshop on Residues of Veterinary Drugs without ADI/MRL related to the establishment of priorities.

173. The Committee agreed to establish a Working Group coordinated by the Delegation of the European Community in order to develop recommendations on how to deal with compounds for which an ADI or MRL could not be set.

---

174. The Committee agreed that a Circular Letter would be sent to collect the following information:

- All compounds with no Codex MRLs used at the national level for food animals;
- Compounds in use that raise health concerns;
- Compounds in use that create trade problems;
- Compounds recommended for inclusion in a negative list and the reasons for their inclusion in that list;
- National or regional MRLs (if any); and
- Other tolerances or application of an analytical limit of detection or determination.

175. On the basis of the information received in reply to the Circular Letter the Working Group would carry out the following tasks:

- Establish two lists of compounds: all compounds used at the national level for which no Codex MRLs exist and all compounds of concern as regards health protection or trade issues;
- Establish criteria for prioritizing all listed compounds;
- Prioritise the listed compounds for future consideration;
- Develop recommendations on how to proceed with consideration of the priority list;
- Discuss the proposed recommendations with the JECFA Secretariat and consider how these relate to the outcomes of the JECFA consideration of the recommendations of the Bangkok FAO/WHO Technical Workshop;
- As necessary, consider other risk management options for dealing with compounds where an ADI cannot be set either due to lack of data or where JECFA has concerns as to the compound; and
- Develop a timetable for action on prioritized substances.

176. The Committee agreed that the new Working Group would prepare a paper for consideration by the Committee by July 2005. The new Working Group would report back to the 16th Session of the Committee through the ad hoc Working Group on Priorities.

177. The Committee expressed its appreciation to the Working Group and to its Chair, Dr Cook (Australia) for their comprehensive work and constructive proposals to address issues related to priorities for evaluation and agreed to convene the ad hoc Working Group on Priorities prior to its next session under the Chairmanship of Australia.

OTHER BUSINESS AND FUTURE WORK (Agenda Item 13)

178. The Committee noted the summary report of the FAO/IAEA Workshop on “Strengthening Capacities for Implementing Codex Standards, Guidelines and the Recommended International Codes of Practice for the Control of the Use of Veterinary Drugs (CRD 3).

DISCUSSION PAPER ON ROUNDING OF ADIS FOR VETERINARY DRUGS PRIOR TO SETTING MRLS (Agenda Item 13a) 27

179. The Delegation of the United States introduced the document and recalled that JECFA rounded the ADI when the ADI, calculated from the No Observed Effect Level (NOEL) using a safety factor, had more than one significant figure. The Delegation highlighted the problems due to the differences between the ADI calculated by JECFA and the ADI set by member governments without rounding, and the significant differences in MRLs in some instances when calculated with a rounded ADI instead of the calculated ADI.

180. The Delegation stated that, in order to address these problems, three options for updating the JECFA procedure could be considered:

26 Australia, Costa Rica, Denmark Germany, France, Korea, the Netherlands, New Zealand, Sweden, Thailand, United Kingdom, United States and IFAH
27 CX/RVDF 04/15/12; CRD 7 (European Community)
i) Round all ADIs up to the next significant figure before setting the MRLs;

ii) Set the MRL using the calculated ADI, and afterwards round the ADI up or down for publication as JECFA’s recommendation; or

iii) Set the MRLs using the calculated ADI and publish the calculated ADI as JECFA’s recommendation.

181. The Delegation proposed that the Committee support the third option in order to make the process of MRL setting more transparent and understandable. This position was supported by several delegations. Some delegations expressed the view that the setting of the ADI was a risk assessment policy issue and therefore the responsibility of the Committee rather than JECFA.

182. The JECFA Secretariat recalled that the rounding of the ADI is based on mathematical considerations and is part of the scientific process, because a precise number would give a misleading impression of certainty. This procedure was included in the Joint FAO/WHO Project to Update the Principles and Methods for the Assessment of Chemicals in Foods. The JECFA Secretariat also pointed out that the setting of the ADI was a risk assessment issue that was the responsibility of risk assessors and that the JECFA had already discussed the issue and did not intend to change this procedure. However, JECFA could consider the implementation of the second option, whereby the calculated ADI was used in MRL setting and the rounded ADI was published as JECFA’s recommendation and this procedure would be clearly described in the JECFA report. Some delegations supported the second option.

183. The Committee discussed how the change in the expression of the ADI might affect MRL setting and whether current MRLs would need to be recalculated and how this would affect the consistency between the procedures followed to establish ADIs and MRLs for pesticides and for veterinary drugs. The Committee noted that the issue of consistency could be addressed in the framework of the Joint FAO/WHO Project.

184. The Committee agreed to support the third option and to refer the above discussion to JECFA for further consideration. The Committee discussed whether this new policy should be applied to future evaluations or to MRLs that had already been recommended by JECFA and were currently under consideration with a view to their finalization.

185. The Committee agreed to apply this policy to future evaluations by JECFA and that the recalculation of MRLs of substances already considered by JECFA would be requested on a case-by-case basis through the routine procedure of prioritization of substances for JECFA evaluation/re-evaluation.

DATE AND PLACE OF NEXT SESSION (Agenda Item 14)

186. The Committee noted that the 16th Session of the Codex Committee on Residues of Veterinary Drugs in Foods was tentatively scheduled to be held in eighteen month time, subject to further discussion between the Codex and United States Secretariats. It was noted that in planning the next Session of the Committee, due consideration will be given to the schedule of the JECFA meeting dealing with residues of veterinary drugs in foods in order to give approximately 6 months for consideration of the next JECFA report before the CCRVDF meets.

187. The Committee noted the kind offer of the Government of Mexico to co-host the next Session.
<table>
<thead>
<tr>
<th>Subject Matter</th>
<th>Step</th>
<th>Action by:</th>
<th>Document Reference (ALINORM 05/28/31)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Draft Maximum Residue Limits for:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Cyhalothrin</td>
<td>8</td>
<td>Governments 28th CAC</td>
<td>Paras 54-56, 62-64, 65-66 and 67-68, Appendix II</td>
</tr>
<tr>
<td>- Flumequine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Neomycin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Dicyclanil</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Proposed Draft Maximum Residue Limits for:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Imidocarb</td>
<td>5/8</td>
<td>Governments</td>
<td>Paras 75-76, Appendix III</td>
</tr>
<tr>
<td>Proposed Draft Code of Practice to Minimize and Contain Antimicrobial Resistance</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Draft Maximum Residue Limits for:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Trichlorfon (metrifonate)</td>
<td>7</td>
<td>16th CCRVDF</td>
<td>Paras 69-73, Appendix IV</td>
</tr>
<tr>
<td>Proposed Draft Maximum Residue Limits for:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Flumequine (in black tiger shrimp)</td>
<td>5</td>
<td>Governments 28th CAC</td>
<td>Paras 62-64, 77-80, 81-82, 83-86, Appendix V</td>
</tr>
<tr>
<td>- Pirlimycin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Cypermethrin and alpha-cypermethrin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Doramectin (in cow’s milk)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Proposed Draft Maximum Residue Limits for:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Ractopamine</td>
<td>4</td>
<td>16th CCRVDF</td>
<td>Paras 87-90, Appendix VI</td>
</tr>
<tr>
<td>Proposed Draft Revised Guidelines for the Establishment of a Regulatory Program for the Control of Veterinary Drug Residues in Foods</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Proposed Draft Revised Part I, II and III of Guidelines for the Establishment of a Regulatory Program for the Control of Veterinary Drug Residues in Foods</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Priority List of Veterinary Drugs Requiring Evaluation of Re-evaluation</td>
<td>1</td>
<td>28th CAC JECFA Governments</td>
<td>Paras 161-170 Appendix IX</td>
</tr>
<tr>
<td>Discussion Paper on Risk Management Methodologies, Including Risk Assessment Policies in the Codex Committee on Residues of Veterinary Drugs in Foods</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Proposed Draft Maximum Residue Limits for:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Phoxim (in cattle tissues and cow’s milk)</td>
<td>discont inued</td>
<td>28th CAC</td>
<td>Paras 51-53, 57-59, 82, Appendix VII</td>
</tr>
<tr>
<td>- Cefuroxime (in cow’s milk)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Cypermethrin (in sheep tissues)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Alpha-cypermethrin (in cattle and sheep tissues and cow’s milk)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Review of Performance-Based Criteria for Methods of Analysis for Veterinary Drug Residues in Foods</td>
<td>discont inued</td>
<td></td>
<td>Para. 154</td>
</tr>
<tr>
<td>Description</td>
<td>Source</td>
<td>Reference</td>
<td></td>
</tr>
<tr>
<td>-----------------------------------------------------------------------------</td>
<td>-----------------</td>
<td>-----------------</td>
<td></td>
</tr>
<tr>
<td>List of Methods of Analysis for Veterinary Drug Residues and Identification of Routine Methods of Analysis</td>
<td>- ad hoc Working Group on MAS 16\textsuperscript{th} CCRVDF</td>
<td>Paras 155-158</td>
<td></td>
</tr>
<tr>
<td>Recommendations on Residues of Veterinary Drugs without ADI/MRL (prioritization of work)</td>
<td>- EC 16\textsuperscript{th} CCRVDF</td>
<td>Paras 171-176</td>
<td></td>
</tr>
</tbody>
</table>
LIST OF PARTICIPANTS
LISTE DES PARTICIPANTS
LISTA DE PARTICIPANTES

Chairperson - President - Presidente

Dr Stephen Sundlof
Director, Center for Veterinary Medicine
US Department of Health and Human Services
Food and Drug Administration
MPN-4
7519 Standish Place
Rockville, MD 20855
United States
Phone: 301-827-2950
Fax: 301-827-4401
Email: ssundlof@cvm.fda.gov

Assistant to the Chairperson – Assistant Au President – Asistente al Presidente

Dr Merton Smith
Special Assistant for International Activities
US Department of Health and Human Services
Food and Drug Administration
MPN-4
7519 Standish Place
Rockville, MD 20855
United States
Phone: 301-827-6239
Fax: 301-827-4401
Email: merton.smith@fda.gov

ANGOLA

Claudia Sicato
Veterinary Chief (Meat Inspection)
Coordenadora Adjunta Do Subcomite de Carnes do
Comite Nacional Para o Codex Alimentarius -
Codex – Angola
Ministerio da Agricultura e do Desenvolvimento
Rural
7-0 Andar Rua Comandante Gika C. p-no 527
Luanda, Angola
Phone: 244-2-92403039
Fax: 244-2-320553
Email: clausicato-3@hotmail.com

AUSTRALIA/AUSTRALIA

Bob Biddle
Deputy Chief Veterinary Officer
Product Integrity, Animal and Plant Health
Australian Government Department of Agriculture
Fisheries and Forestry
GPO Box 858
Canberra, ACT 2601, Australia
Phone: 61 2 6272 5364
Fax: 61 2 6272 3150
Email: bob.biddle@daff.gov.au
Lee Cook  
Veterinarian (Chemical Control)  
NSW Agriculture  
Locked Bag 21  
Orange, NSW 2800, Australia  
Phone: 61 2 6391 3722  
Fax: 61 2 6391 3740  
Email: lee.cook@agric.nsw.gov.au

Peter Holdsworth  
Director  
Scientific and Regulatory Affairs (Agvet Chemicals)  
Avicare Limited  
Locked Bag 916  
Canberra, ACT 2601, Australia  
Phone: 61 2 6230 6399  
Fax: 61 2 6230 6355  
Email: sraagvet@avcare.org.au

Jason Lutze  
Project Manager  
National Residue Survey  
Australian Government Department of Agriculture Fisheries and Forestry  
GPO Box 858  
Canberra, ACT 2601, Australia  
Phone: 61 2 6272 3445  
Fax: 61 2 6272 4023  
Email: Jason.lutze@daff.gov.au

Brett Yeomans  
A/g Group Manager, Regulated Drugs and Chemicals  
Australian Government, National Measurement Institute  
GPO Box 1844  
Canberra, ACT, 2601, Australia  
Phone: +61-2-62136146  
Fax: +61-2-62136815  
Email: brett.yeomans@measurement.gov.au

BELGIUM/BELGIQUE/BÉLGICA

Edith Hoc  
Veterinary Officer  
Federal Public Service  
"Health, Food Chain Safety and Environment"  
Cite Administrative de l'Etat  
Arcades  
Bd Pacheco, 19 Bte 5  
Bruxelles, B-1010, Belgium  
Phone: 32-2-210-5219  
Fax: 32-2-210-5264  
Email: edith.hoc@health.fgov.be

Herman Vanbekevoort  
Veterinary Expert  
Federal Agency for the Safety of the Food Chain  
WTC III, 8e floor  
Simon Bolivarlaan 30  
1000 Brussels, Belgium  
Phone: 32-2-208 38 85  
Fax: 32-2-208 38 66  
Email: herman.vanbekevoort@favv.be

BRAZIL/BRÉSIL/BRASIL

Marcia Donner  
First Secretary  
Brazilian Embassy  
3006 Massachusetts Ave., NW  
Washington, DC 20008, United States  
Phone: 202-238-2718

Ricardo Rego Pamplona  
Coordinator of Veterinary Products  
Department of Animal Health  
Ministry of Agriculture, Livestock and Supply  
Esplanada, Bloco D. Anexo A  
Sala 306  
Brasilia, DF Brazil  
Phone: 61 218 2230  
Fax: 61 323 5936  
Email: rpamplona@agricultura.gov.br

Maria Angelica Ribeiro de Oliveira  
Veterinary Federal Inspector  
Ministry of Agriculture, Livestock and Supply  
Department of Promotion and Inspection of Animal Production  
Esplanada dos Ministerios - Bloco B  
Anexo B-1 Andar-Sala 116  
Brasilia-DF, 70043-900, Brazil  
Phone: +55 61 218-2438  
Fax: +55 61 218-2727  
Email: ribeiro@agricultura.gov.br

Joao Palermo-Neto  
Professor of Pharmacology  
University of Sao Paulo  
Av. Renato Paes de Barros  
No. 322 apts. 102  
Sao Paulo-SP, 04530-000, Brazil  
Phone: 55-11-30917957  
Fax: 55-11-30918775  
Email: jpalermo@usp.br
Lucas Medeiros Dantas  
Manager  
National Health Surveillance Agency  
Office of Foods Science and Technology Actions  
SEPN 511 Bloco A Ed. Bittar II 2 andar  
Brasilia DF, 70.750-541, Brazil  
Phone: (61) 448 6284/6285  
Fax: (61) 448 6274  
Email: gacta@anvisa.gov.br

BURKINA FASO

Drissa Siri  
Directeur General  
Direction Generale Des Productions Animales  
Ministere Des Ressources Animales  
03 BP 7026  
Ouagadougou, 03, Burkina Faso  
Phone: (226) 70-25-57-07  
Fax: (226) 50-31-74-76  
Email: idrissiri@yahoo.fr

CANADA/CANADÁ

Jacques Asselin  
Chemist  
2700, rue Einstein  
Bureau C.2.105  
St-Foy, Quebec G1P 3W8, Canada  
Phone: 418-266-4440 x213  
Fax: 418-266-4438  
Email: jacques.asselin@agr.gouv.qc.ca

Joe Boison  
Senior Research Scientist  
Centre for Veterinary Drug Residues  
Canadian Food Inspection Agency  
Saskatoon Laboratory  
116 Veterinary Road  
Saskatoon, Saskatchewan S7N 2R3, Canada  
Phone: 306-975-5358  
Fax: 306-975-5711  
Email: jboison@inspection.gc.ca

Paul Dick  
Technical & Regulatory Manager  
Elanco Animal Health  
Canadian Animal Health Institute  
160 Research Lane  
Suite 102  
Guelph, Ontario N1G 5B2, Canada  
Phone: 519-763-7777  
Fax: 519-763-7407  
Email: p.dick@elanco.com

Peter Lau  
Drug Evaluator  
Human Safety Division  
Veterinary Drugs Directorate  
Health Canada  
Holland Cross Complex  
11 Holland Avenue  
Suite 14  
Ottawa, Ontario K1A 0L9, Canada  
Phone: 613-946-2597  
Fax: 613-957-3861  
Email: peter_lau@hc-sc.gc.ca

Dennis Lein  
Senior Advisor, Food Regulatory Program  
Bureau of Food Regulatory  
International and Interagency Affairs  
Food Directorate  
Health Canada  
Building #7, Room 2354  
P.L. 0702C1, Tunney's Pasture  
Ottawa, Ontario K1A 0L2, Canada  
Phone: 613-957-1751  
Fax: 613-941-3537  
Email: dennis_lein@hc-sc.gc.ca

James MacNeil  
Head, Centre for Veterinary Drug Residues  
Canadian Food Inspection Agency  
Saskatoon Laboratory  
116 Veterinary Road  
Saskatoon, Saskatchewan S7N 2R3, Canada  
Phone: 306-975-5347  
Fax: 306-975-5711  
Email: jmacneil@inspection.gc.ca

Jean Szkotnicki  
President  
Canadian Animal Health Institute  
160 Research Lane  
Suite 102  
Guelph, Ontario N1G 5B2, Canada  
Phone: 519-763-7777  
Fax: 519-763-7407  
Email: jszk@cahi-icsa.ca
Arnost Vilim  
A/Director, Human Safety Division  
Veterinary Drugs Directorate  
Health Products and Food Branch, Health Canada  
Holland Cross Complex  
11 Holland Avenue  
Ottawa, Ontario  K1A 0L9, Canada  
Phone: 613-957-3880  
Fax: 613-957-3861  
Email: Arnost_vilim@hc-sc.gc.ca

CHINA/CHINE

Zhang Yuxiang  
Director-General  
Department of Market & Economy Information  
Ministry of Agriculture  
11 Nongzhanguan Nanli  
Beijing, P.R.  100026, China  
Phone: 86-10-641 93152  
Fax: 86-10-641 93154  
Email: zhangyuxiang@agri.gov.cn

Ma Bing  
Research Assistant  
Chinese Academy of Fishery Sciences  
Yongding Road  
Fengtai District  
Beijing,  100039, China  
Phone: 86-10-68679396  
Fax: 86-10-68676685  
Email: skyzbb@vip.sina.com

Luk Geraldine  
Veterinary Officer  
HKSAR China  
TAI Lung Veterinary Laboratory  
Lin Tong Mei, Sheung Shui  
Hong Kong, China  
Phone: 852-24552271  
Fax: 852-24618421  
Email: geraldine_luk@afcd.gov.hk

Li Huijiao  
Professor  
China Institute of Veterinary Drug Control  
8 Southern Street of Zhong-Guan-Cun  
Beijing,  100081, China  
Phone: 86-10-62150572  
Fax: 86-10-62150039  
Email: lihuijiao@ivdc.gov.cn

Shen Jianzhong  
Professor/Director  
China Agricultural University  
Beijing,  100094, China  
Phone: 86-10-627 32803  
Fax: 86-10-62731032  
Email: sjz@cau.edu.cn

Jai Man-ho  
Veterinary Officer  
Hong Kong Government, China  
43/F  
Queensway Government Office  
Queensway,  
Hong Kong, China  
Phone: 852-28675427  
Fax: 852-25218067  
Email: jmhjai@fehd.gov.hk

Yinliang Wu  
Engineer  
Division of Quality Inspection, National Animal  
Husbandry & Veterinary Service, M.O.A., P.R. China  
Quality Control & Inspection Center for Domestic Animal Products, M.O.A  
20 Maizidian Street  
Chaoyang District  
Beijing,  100026, China  
Phone: 86-10-641 94682  
Fax: 86-10-641 94681  
Email: wuy1985@163.net

Huang Yaoling  
Research Assistant  
China Institute of Veterinary Drug Control  
8 Southern Street of Zhong-Guan-Cun  
Beijing,  100081, China  
Phone: 86-10-62158844-3405  
Fax: 86-10-62158844-3382  
Email: huangyaoling@ivdc.gov.cn

Zonghui Yuan  
Professor/ Director  
College of Veterinary Medicine  
Huazhong Agricultural University  
Shizishan Street  
Hongsan District  
Wuhan, Hubei  430070, China  
Phone: 0086-27-87671336  
Fax: 0086-27-87288632  
Email: yuam5802@public.wh.hb.cn
Li Zhaoxin
Associate Professor
National Center for Quality Supervision and Test for Aquatic Products
Yellow Sea Fishery Research Institute
Chinese Academy of Fishery Sciences
106 Nanjing Road
Qingdao, 266071, China
Phone: 86-532-583 6348
Fax: 86-532-582 5917
Email: lizx@ysfri.ac.cn

COLOMBIA/COLOMBIE
McAllister Tafur Garzan
Head of Delegation - Food Security Coordinator
Instituto Colombiano Agropecuario ICA
Coordinador Grupo Inicidad en Cadenas Agroalimentarias Pecuarias
Calle 37 8-43 piso 5
Bogota, Colombia
Phone: 57-1-2325315
Fax: 57-1-2324695
Email: tafur@ica.gov.co

COSTA RICA
Marco Oviedo
Chief of Department Registration Veterinary Medicine
Ministry of Agriculture and Livestock
Buildings MAG on Barreal de Heredia
Costa Rica
Phone: 506-260-8300, 260-93-49
Fax: 506-260-5483
Email: moviedo@protecnet.go.cr

Jose Rojas
Chief of Section Toxic Residue
Ministry of Agriculture and Livestock
Buildings MAG on Barreal de Heredia
Costa Rica
Phone: 506-260-8300 ext. 2177
Fax: 506-260-5483
Email: jrojas@protecnet.go.cr / joluroma@yahoo.com

CUBA
Maria Torano Martin
Director, National Center on Food Hygiene
Institute of Veterinary Medicine Minister of Agriculture
Heredia No. 366. 10 de Octubre
e/San Mariano y Vista Alegre Vibora
Cuba
Phone: 53 7 577149
Fax: 53 7 306615
Email: maria.torano@infomed.sld.cu

CZECH REPUBLIC/RÉPUBLIQUE TCHÈQUE/REPUBLICA CHECA
Vera Billova
Institute for State Control of Veterinary Medicine
Hudeova 56a
Brno, 62100, Czech Republic
Phone: 420541210022
Fax: 420541210026
Email: billova@uskvbl.cz

DENMARK/DANEMARK/DINAMARCA
Per Henriksen
Senior Veterinary Officer
Danish Veterinary and Food Administration
Morkhoj Bygade 19
Seborg, DK-2860, Denmark
Phone: 45 33 95 60 00
Fax: 45 33 95 66 19
Email: pesh@fvst.dk

Kim Petersen
Scientific Adviser
Danish Veterinary and Food Administration
Morkhoj Bygade 19
Seborg, DK-2860, Denmark
Phone: 45 33 95 60 00
Fax: 45 33 95 60 01
Email: kimp@fvst.dk
DOMINICAN REPUBLIC/RÉPUBLIQUE DOMINICAINE/RÉPUBLICA DOMINICANA

Lissette Gomez
Veterinarian
Analisis de Riesgo
Direccion General de Ganaderia
Santo Domingo, Dominican Republic
Phone: 809-535-8996
Fax: 809-440-6415
Email: lissette0912@hotmail.com

EGYPT/ÉGYPTE/EGIPTO

Hussein Mansour
Agricultural Minister Plenipotentiary & Head of the Agricultural Office
Embassy of the Arab Republic of Egypt
3521 International Court, NW
Washington, DC 20008, United States
Phone: 202-966-2080
Fax: 202-895-5493
Email: hmkmansour@aol.com

EUROPEAN COMMUNITY/COMMUNAUTÉ EUROPÉENNE/COMUNIDAD EUROPEA

Jerome Lepeintre
Administrator
European Commission
Rue de la Loi 200
F101 4/78 - B-1049 Brussels, Belgium
Phone: 32 2 299 3701
Fax: 32 2 299 8566
Email: jerome.lepeintre@cec.eu.int

Gudrun Gallhoff
Health and Consumer Protection Directorate-General
European Commission
Rue de la Loi 200
B-1049 Brussels, Belgium
Phone: 32-2-296-71-28
Fax: 32-2-299-18-56
Email: gudrun.gallhoff@cec.eu.int

Anne Gautrais
Enterprise Directorate-General
European Commission
Rue de la Loi 200
B – 1049 Brussels, Belgium
Phone: 32-2-295-29-84
Fax: 32-2-299-80-46
Email: anne.gautrais@cec.eu.int

Kornelia Grein
Head of Sector-Safety of Veterinary Medicines
European Medicines Agency
7, Westferry Circus, Canary Wharf
London, E14 4HB, United Kingdom
Phone: 44-207-4188432
Fax: 44-207-4188447
Email: kornelia.grein@emea.eu.int

FINLAND/FINLANDE/FINLANDIA

Erkki Koskinen
Veterinary Officer
Ministry of Agriculture and Forestry
P.O. Box 30
Government
Fin, 00023, Finland
Phone: 358-9-1605-3388
Fax: 358-9-1605-3338
Email: erkki.koskinen@mmm.fi

FRANCE/FRANCIA

Gerard Moulin
Head of Delegation
AFSSA – ANMV
International Affairs
La Haute Marche Javene
BP 90203
Fougeres, 35302, France
Phone: 33 (0)2 99 94 78 58
Fax: 33 (0)2 99 94 78 99
Email: g.moulin@anmv.afssa.fr

Pascal Audebert
SGCI-Gestion du Codex Alimentarius
Charge de Mission
2 Boulevard Diderot
Paris, Cedex 12 75572, France
Phone: 33 (0)1 44 87 16 03
Fax: 33 (0)1 44 87 16 04
Email: pascal.audebert@sgci.gouv.fr

Georges Monsallier
SIMV
50 Rue de Paradis
11 Rue des Messageries
Paris, 75010
France
Phone: 33 01 53 34 43 40
Fax: 33 01 53 34 43 44
Email: georges.monsallier@wanadoo.fr
Jean-Pierre Orand  
Ministere of Agriculture  
DGAL  
251, rue de Vaugirard  
Paris, Cedex 15, 75732, France  
Phone: 33 (0)1 49 55 58 43  
Fax: 33 (0)1 49 55 40 22  
Email: jean-pierre.orand@agriculture.gouv.fr

Ilse-Dore Schuett  
Bundesministerium fur Gesundheit und Soziale  
Sicherung  
Am Propsthof 78a  
Bonn, D-53108, Germany  
Phone: 49-0-228-941-1190  
Fax: 49-0-228-941-4967  
Email: ilse-dore.schuett@bmgs.bund.de

Undine Buettner-Peter  
Head of Delegation  
Federal Ministry of Consumer Protection, Nutrition and Agriculture  
Rochusstrasse 1  
Bonn, D-53123, Germany  
Phone: 49-0-228-529-4644  
Fax: 49-0-228-529-4946  
Email: 326@bmvel.bund.de

GUATAMALA  
Carlos Menendez  
Organismo Internacional d Sanidad Agropecuaria  
21 av. 3-12 Zone 15  
Vista Hermosa 1  
Guatamala  
Phone: 2369 5902  
Fax: 2365 8599  
Email: cmenendez@oirsa.org.gt

Ludwig Klostermann  
Bayer AG  
Animal Health Division  
Business Planning and Administration  
Policy and Issues Management  
Leverkusen, D-51368, Germany  
Phone: 49-0-2173-383-861  
Fax: 49-0-2173-383-539  
Email: ludwig.klostermann.lk@bayer-ag.de

REINHARD KROKER  
Bundesamt fur Verbraucherschutz und Lebensmittelsicherheit  
Dienststelle Berlin  
Diedersdorfer Weg 1  
Berlin-Marienfelde, D-12277, Germany  
Phone: 49-0-1888-412-2364  
Fax: 49-0-1888-412-2965  
Email: reinhard.kroker@bvl.bund.de

Ilse-Dore Schuett  
Bundesministerium fur Gesundheit und Soziale  
Sicherung  
Am Propsthof 78a  
Bonn, D-53108, Germany  
Phone: 49-0-228-941-1190  
Fax: 49-0-228-941-4967  
Email: ilse-dore.schuett@bmgs.bund.de

GUATAMALA  
Carlos Menendez  
Organismo Internacional d Sanidad Agropecuaria  
21 av. 3-12 Zone 15  
Vista Hermosa 1  
Guatamala  
Phone: 2369 5902  
Fax: 2365 8599  
Email: cmenendez@oirsa.org.gt

Martin Schneider  
Bundesverband fuer Tiergesundheit e.V.  
Geschafftsfuehrer  
Aennchenplatz 6  
Bonn, D-53173, Germany  
Phone: 49-0-228-318-2986  
Fax: 49-0-228-318-2986  
Email: m.schneider@bft-online.de

Ilse-Dore Schuett  
Bundesministerium fur Gesundheit und Soziale  
Sicherung  
Am Propsthof 78a  
Bonn, D-53108, Germany  
Phone: 49-0-228-941-1190  
Fax: 49-0-228-941-4967  
Email: ilse-dore.schuett@bmgs.bund.de

GUATAMALA  
Carlos Menendez  
Organismo Internacional d Sanidad Agropecuaria  
21 av. 3-12 Zone 15  
Vista Hermosa 1  
Guatamala  
Phone: 2369 5902  
Fax: 2365 8599  
Email: cmenendez@oirsa.org.gt

Lorena Kovacsics  
Chairman of the Hungarian CC RVDF  
National Food Investigation Institute  
Mester-u. 81  
Budapest, H-1095, Hungary  
Phone: 36-1-456-3021  
Fax: 36-1-215-6858  
Email: kovacsil@oai.hu

Miklos Suth  
Executive Director  
National Food Investigation Institute  
Mester-u. 81  
Budapest, H-1095, Hungary  
Phone: 36-1-456-3012  
Fax: 36-1-215-6858  
Email: suthm@oai.hu
INDONESIA/INDONÉSIE

Rismansyah Danasaputra  
(Head of Delegation)  
Director  
Ministry of Agriculture  
Directorate for Processing and Marketing of  
Livestock Production  
Kanpus Departemen Pertanian, GD D, Lt. III  
Jl. Harsono RM No. 3, Ragunan, Pasar Minggu  
Jakarta Selatan 12550, Indonesia  
Phone: 021-78842044  
Fax: 021-7815880  
Email: risman@deptan.go.id

Metrawinda Tunus  
Agricultural Attache  
Embassy of Indonesia  
Phone: 202-775-5340  
Fax: 202-775-5343

IRELAND/IRLANDE/IRLANDA

Ciaran O’Sullivan  
Veterinary Officer  
Food Safety Authority of Ireland  
Abbey Court  
Lower Abbey Street  
Dublin 1, Ireland  
Phone: 353-1-817-1361  
Fax: 353-1-817-1301  
Email: cosullivan@fsai.ie

Paul Rafter  
Superintending Veterinary Inspector  
Department of Agriculture & Food  
Central Meat Control Laboratory  
Abbotstown  
Castleknock  
Dublin, 15, Ireland

ITALY/ITALIE/ITALIA

Ciro Impagnatiello  
Ministero delle Politiche Agricole e Forestali  
Via Venti Settembre 20  
00187 Rome, Italy  
Phone: 39 06 4665 6511  
Fax: 39 06 4880 273  
Email: ciroimpa@tiscali.it

JAPAN/JAPON/JAPÓN

Satoshi Motomura  
(Head of Delegation)  
Deputy Director  
Ministry of Agriculture, Forestry and Fisheries  
Animal Health and Animal Products Safety  
Division  
Food Safety and Consumer Affairs Bureau  
1-2-1 Kasumigaseki  
Chiyoda-ku  
Tokyo, 100-8950, Japan  
Phone: +81-3-3502-8097  
Fax: +81-3-3502-8275  
Email: satoshi_motomura@nm.maff.go.jp

Takuya Kondo  
Assistant Director  
Standards and Evaluation Division  
Department of Food Safety  
Pharmaceutical and Food Safety Bureau, Ministry of Health, Labor and Welfare  
1-2-2 Kasumigaseki  
Chiyoda-ku  
Tokyo, 100-8916, Japan  
Phone: 81-3-3595-2341  
Fax: 81-3-3501-4868  
Email: kondo-takuya@mhlw.go.jp

Toshio Takahashi  
Chief of Antibiotics Section  
National Veterinary Assay Laboratory  
1-15-1 Tokura  
Kokubunji  
Tokyo, 185-8511, Japan  
Phone: 042-321-1841  
Fax: 042-321-1769  
Email: takahat@mval.go.jp

Yoshiyuki Nagao  
Official  
Risk Assessment Division  
Food Safety Commission Secretariat  
2-13-10 Prudential Tower 6F  
Nagata-cho  
Tokyo, Chiyoda-ku 100-8989, Japan  
Phone: 81-3-5251-9150  
Fax: 81-3-3591-2236  
Email: yoshiyuki.nagao@op.cao.go.jp
Keisuke Okano
Technical Adviser
Japan Food Hygiene Association
2-6-1 Jinguumae
Shibuya-ku
Tokyo, 150-0001
Japan
Phone: 81-3-3403-2111
Fax: 81-3-3478-0059
Email: keisuke.okano@spcorp.com

Ryo Saito
Technical Adviser
Japan Food Hygiene Association
2-6-1 Jinguumae
Shibuya-ku
Tokyo, 150-0001, Japan
Phone: 81-3-3403-2111
Fax: 81-3-3478-0059
Email: saito-ryo@zenoaq.jp

KENYA

Jactone Waga Jalang’o
Chief Food Hygiene Officer
Ministry of Livestock and Fisheries Development,
Department of Veterinary Services,
Veterinary Research Laboratories
P.O. Private Bag Kangemi
Nairobi, 00625, Kenya
Phone: 020 63 1289 or 07 22 380 360
Fax: 020 63 1273 or 020 63 1790
Email: jjalango2000@yahoo.com

Wangai Moses Mwangi
Standards Officer
Kenya Bureau of Standards
Food and Agriculture Section
PO Box 54974
Nairobi, 00200, Kenya
Phone: +254 502210; 0722325995
Email: wangaim@kebs.org

LAO PEOPLE’S DEMOCRATIC REPUBLIC/RÉPUBLIQUE DÉMOCRATIQUE POPULAIRE LAO/REPÚBLICA DEMOCRÁTICA POPULAR LAO

Mahanakhone Souriya
Director General
Ministry of Agriculture and Forestry
Department of Livestock and Fisheries
P.O. Box 811
Vientiane, Laos
Phone: 856-21-416932
Fax: 856-21-415674
Email: ahr9438@laotel.com

MALAYSIA/MALAISIE/MALASIA

Zaliha Abdullah
Senior Veterinary Officer
Ministry of Agriculture and Agro-based Industry
Department of Veterinary Services
8th & 9th Floor
Wisma Chase Perdana
Damansara Heights
Kuala Lumpur, 50630, Malaysia
Phone: 603-2094-0077 x175
Fax: 603-2093-5804
Email: zaliha@jph.gov.my

MEXICO/MEXIQUE/MÉXICO

Octavio Carranza de Mendoza
Director de Importacion Exportacion Servicios y Certificacion Pecuaria Direccion General de Salud Animal Secretaria de Agricultura, Ganaderia,
Desarrollo Rural, Pesca y Alimentacion (Sagarpa) Mexico
Phone: 91-83-1000 x33946
Email: carranza@senasica.sagarpa.gob.mx
Mongolia/Mongolie

Batsuuri Nantsag
State Secretary
Ministry of Food and Agriculture
Government Bldg #9
Enkhataruan Avenue 16A
Ulaanbaatar, 210349
Mongolia
Phone: (976)-11-262802
Fax: (976)-11-452554
Email: batsuuri@mofa.pmis.gov.mn;
ng_batsuuri@yahoo.com

Netherlands/Pays Bas/Países Bajos

Gijs Theunissen
Head of Delegation
Ministry of Agriculture, Nature and Food Quality
Department of Food Quality and Animal Health
Policy Affairs Veterinary Drugs and Hormones
P.O. Box 20401
2500 EK The Hague, the Netherlands
Phone: 31-70-378-4594
Fax: 31-70-378-6141
Email: g.t.j.m.theunissen@minlnv.nl

Dick Groothuis
Sr. Veterinary Public Health Officer
Food & Consumer Product Safety Authority
P.O. Box 19506
2500 CM
The Hague, the Netherlands
Phone: 31-70-448-4903
Fax: 31-70-448-4061
Email: dick.groothuis@vwa.nl

Arie Ottevanger
Policy Coordinator Veterinary Food Safety Policy
Ministry of Health, Welfare and Sport
P.O. Box 20350
2500 EJ Den Haag, the Netherlands
Phone: 31 70 340 68 86
Fax: 31 70 340 55 54
Email: a.ottevanger@minvws.nl

Nathalie Scheidegger
Policy Manager Risk Management Food and Feed
Department of Food Quality and Animal Health
Ministry of Agriculture, Nature and Food Quality
P.O. Box 20401
2500 EK The Hague, the Netherlands
Phone: 31-70-378-4693
Fax: 31-70-378-6141
Email: n.m.i.scheidegger@minlnv.nl

Rainer Stephany
Director, EU Community Reference Laboratory
VWS/RIVM National Institute of Public Health
P.O. Box 1
3720 BA Bithoven, the Netherlands
Phone: 31 30 274 2717
Fax: 31 30 274 4403
Email: Rainer.Stephanynivm.nl

Philip Landon
Administrator
Council of the European Union
Rue de la Loi 175
Brussels, B-1048, Belgium
Phone: 0032-2-235-4966
Fax: 0032-2-285-7928
Email: philip.landon@consilium.eu.int

New Zealand/Nouvelle-Zélande/Nueva Zelandia

William (Bill) Jolly
Deputy Director (Animal Products)
New Zealand Food Safety Authority
P.O. Box 2835
Wellington, New Zealand
Phone: 64 4 463 2621
Fax: 64 4 463 2643
Email: bill.jolly@nzfsa.govt.nz

Debbie Morris
Director, ACVM Group
New Zealand Food Safety Authority
PO Box 2835
Wellington, New Zealand
Phone: 64-4-463-2541
Fax: 64-4-463-2501
Email: debbie.morris@nzfsa.govt.nz

John Reeve
Programme Manager (Toxicology & Residues)
New Zealand Food Safety Authority
P.O. Box 2835
Wellington, New Zealand
Phone: 64-4-463-2533
Fax: 64-4-463-2566
Email: john.reeve@nzfsa.govt.nz
### NORWAY/NORVÈGE/NORUEGA

**Christin Schultz**  
Adviser  
Norwegian Food Safety Authority  
Head Office  
P.O. Box 383  
Brumunddal, N-2381, Norway  
Phone: 47-23-21-67-70  
Fax: 47-23-21-68-01  
Email: chsch@mattilsynet.no

**Tone Normann Asp**  
Norwegian School of Veterinary Science  
Department of Food Safety and Infection Biology  
P.O. Box 8146 Dep.  
Oslo, 0033, Norway  
Phone: 47-2296-4832  
Fax: 47-2296-4850  
Email: tone.asp@veths.no

**Kari Grave**  
Professor  
Norwegian School of Veterinary Science  
Department of Food Safety and Infection Biology  
Box 8146 Dep  
Oslo, 0033, Norway  
Phone: 47-22-96-49-88  
Fax: 47-22-96-47-52  
Email: kari.grave@veths.no

### PERU/PÉROU/PERÚ

**Romulo Sevilla Juarez**  
Psje Francisco de Zela No. 150 Piso 10  
Edif. Del Ministerio de Trabajo  
Lima 11, Peru  
Phone: (511) 424-7072  
Fax: (511) 424-7072  
Email: rsevilla@senasa.gob.pe

### PORTUGAL

**Helena Ponte**  
Head of Division  
Direcção - geral de Veterinaria  
Largo da Academia Nacional de Belas Artes  
Mº 2, 1149-105 Lisboa, Portugal  
Phone: 351 21 3239536  
Fax: 351 21 3239565  
Email: Helena_Ponte@dgv.min-agricultura.pt

### REPUBLIC OF KOREA/RÉPUBLIQUE DE CORÉE/REPÚBLICA DE COREA

**Sang-Hee Jeong**  
(Head of Delegation)  
Deputy Director  
Toxicology & Biochemistry Division  
National Veterinary Research & Quarantine Service  
Ministry of Agriculture and Forestry  
480 Anyang 6 Dong  
Anyang City, 430-016, Korea  
Phone: 82-31-467-1837  
Fax: 82-31-467-1845  
Email: jeongsh@nvrqs.go.kr

**Sungmyung Bae**  
Senior Researcher  
Food Sanitation Council, Codex Office  
Food Policy Division  
Bureau of Health Policy, Ministry of Health & Welfare  
#1 Jooang-dong; Gwacheon-si  
Gyeong gi-do, 427-721, Korea  
Phone: 82-2-504-6233  
Fax: 82-2-503-7552  
Email: smbae_23@mohw.go.kr

**Dongmi Choi**  
Deputy Director  
Korea Food & Drug Administration  
Residue and Chemicals Division  
#5 Nokbun-dong  
Eunpyung-gu  
Seoul, 122-704, Korea  
Phone: 82-2-380-1674  
Fax: 82-2-380-1378  
Email: mechoi@kfda.go.kr

### POLAND/POLOGNE/POLONIA

**Tadeusz Wijaszka**  
Director General  
National Veterinary Research Institute  
Pulawy, 24-100, Poland  
Phone: 488 1886 5270  
Fax: 488 1887 7100  
Email: t.wijaszka@piwet.pulawy.pl
Jiyoon Jeong
Senior Researcher
Reviewer & Scientific Officer
Korea Food & Drug Administration
Residue & Chemicals Division
5 Nokbun-dong
Eunpyung-gu
Seoul, 122-704, Korea
Phone: 82 2 380 1875
Fax: 82 2 380 1378
Email: stopyoon@kfda.go.kr

RUSSIAN FEDERATION/FÉDÉRATION DE RUSSIE/FEDERACIÓN DE RUSIA

Alexander Panin
Director
All Russian States Center for Quality and Standardization of Veterinary Drug and Feedstuff
Ministry of Agriculture of the Russian Federation
Zvenigorodskor Shosse 5
Moskva, 1230022, Russia
Phone: 7-095 253 1491
Fax: 7-095 253 1491
Email: vgnki-vet@mtu-net.ru

SOUTH AFRICA/AFRIQUE DE SUD/SUDÁFRICA

Moroe Rulashe
Deputy Director
Directorate: Food Safety and Quality Assurance
Department of Agriculture
Private Bag X343
Pretoria, 0001, South Africa
Phone: 27 12 3196671
Fax: 27 12 3196764
Email: mmalencoeM@nda.agric.za

SPAIN/ESPAGNE/ESPAÑA

Santiago Gutierrez del Arroyo
Agencia Española de Seguridad Alimentaria
Ministerio Sanidad y Consumo
c/ Alcaca 56
Madrid, 28071, Spain
Phone: +34 91 3380620
Fax: +34 91 3380238
Email: sgtierrez@msc.es

Inmaculada Mendez Martinez
Subdirección General Sanidad Animal
Ministerio Agricultura, Pesca y Alimentacion
c/o Alfonso XII 62
Madrid, 28071, Spain
Phone: 0034 913 473 772
Fax: 0034 913 478 8299
Email: imendez@mapya.es

SWEDEN/SUÉDE/SUECIA

Kajsa Gustavsson
(Head of Delegation)
Senior Veterinary Inspector
National Food Administration
Food Standards Department
Box 622
SE-751 26
Uppsala, Sweden
Phone: 46-18-17-56-86
Fax: 46-18-17-56-10
Email: kajsa.gustavsson@slv.se

Hakan Johnsson
Chief Chemist
National Food Administration
Box 622
SE-751 26
Uppsala, Sweden
Phone: 46-18-17-57-05
Fax: 46-18-10-58-48
Email: hajo@slv.se

SWITZERLAND/SUISSE/SUIZA

Philippe Etienne
First Secretary (Economic Affairs)
Embassy of Switzerland
2900 Cathedral Avenue, N.W.
Washington, DC 20008
United States
Phone: 202-745-7922
Fax: 202-387-2564
Email: philippe.etienne@was.rep.admin.ch
Thomas Skripsky  
Toxicologist  
Novartis Animal Health Inc./IFAH Europe  
WRO-1032.2.66  
CH-4002 Basel, Switzerland  
Phone: 41 61 697 66 00  
Fax: 41 61 697 70 80  
Email: thomas.skripsky@ah.novartis.com

Jean Vignal  
Regulatory Affairs  
Nestec Ltd.  
Avenue Nestle 55  
Vevey, CH-1800, Switzerland  
Phone: 41-21-924-35-01  
Fax: 41-21-924-45-47  
Email: jean.vignal@nestle.com

THAILAND/THAILANDE/TAILANDIA

Danis Davitiyananda  
(Head of Delegation)  
Associated Professor  
National Bureau of Agriculture  
Commodity and Food Standards  
Ministry of Agriculture and Cooperatives  
185/1 (16) Sareethai Lane, Sareethai Street  
Klongjon, Bangkopi  
Bangkok, 10240, Thailand  
Phone: 662-375-8985  
Fax: 662-377-8777

Usa Bamrungbhuet  
Standards Officer  
National Bureau of Agriculture  
Commodity and Food Standards  
Ministry of Agriculture and Cooperatives  
Rajadamnern Nok. Avenue  
Bangkok, 10200, Thailand  
Phone: 662-283-1693  
Fax: 662-280-3899  
Email: usa@aefs.go.th; usa_bam@hotmail.com

Sasi Jaroenpoj  
Veterinary Officer  
Department of Livestock Development  
Phayathai Rd.  
Bangkok, 12000, Thailand  
Phone: 02 963 9202  
Fax: 02 963 9216

Orawan Kaewprakaisangkul  
Director, Lab Services Dept.  
Industrial Development Foundation  
National Food Institute  
2008 Soi Charansanitwong  
40 Charansanitwong Rd  
Bangyeekhan Bangphlad  
Bangkok, 10700, Thailand  
Phone: 662-886-8088  
Fax: 662-886-8106  
Email: orawan@nfi.or.th

Somkiat Kanchanakhan  
Fishery Biologist  
Office of Agricultural Affairs  
Royal Thai Embassy  
1024 Wisconsin Ave., N.W.  
Washington, DC 20007, United States  
Phone: 202-338-1543  
Fax: 202-338-1549  
Email: kanchanakhan@yahoo.com

Pischa Lusananda  
Drug Control Division  
Food and Drug Administration  
Tiwanon Rd, Nonthaburi 11000  
Thailand  
Email: pischa@fda.woph-go.th

Sujittra Phongvivat  
Veterinary Officer  
Department of Livestock Development  
Phayathai Rd.  
Bangkok, 12000, Thailand  
Phone: 02 963 9202  
Fax: 02 963 9216

Nantana Posanacharoen  
Senior Veterinary Officer  
National Bureau of Agriculture  
Commodity and Food Standards  
Ministry of Agriculture and Cooperatives  
Rajadamnern Nok. Avenue  
Bangkok, 10200, Thailand  
Phone: 662-283-1693  
Fax: 662-280-3899

Boonpeng Santiwattanatam  
Vice-Chairman of Food Processing Industry Club  
Queen Sirikit National Convention Center  
Zone C, 4th Floor, 60 New Rachadapisek Rd.  
Klongtoey, Bangkok 10110, Thailand  
Phone: 662-229-4255  
Fax: 662-229-4941  
Email: boonpeng@cpf.co.th
Assoc Prof Palarp Sinhaseni, Ph.D
Institute of Health Research
Chulalongkorn University
Chulalongkorn Soi 62
Bangkok 10330
Thailand
Phone: 66-2-218-8152
Fax: 66-2-253-2395
Email: spalarp@chula.ac.th

Jirawan Yamprayoon
Director, Fish Inspection and Quality Control Division
Department of Fisheries
Ministry of Agriculture and Cooperatives
Kasetsart Campus, Jatuchak
Bangkok, 10900, Thailand
Phone: 66-2558-0133
Fax: 66-2558-0136
Email: jirawany@fisheriers.go.th

UNITED ARAB EMIRATES/EMIRATES
ARABES UNIS/EMIRATOS ÁRABES UNIDOS
Waheed Al Awadi
Head of Chemistry Lab Unit
Food and Environment Laboratory Section
Dubai Central Lab Department
Dubai – UAE, United Arab Emirates
Phone: +97150-6565491
Fax: +9714-3358448
Email: waawadi@dm.govae

UNITED KINGDOM/ROYAUME-UNI/REINO
UNIDO
John FitzGerald
Director of Policy
Veterinary Medicines Directorate
Woodham Lane, New Naw
Addlestone, Surrey
KT 15 3LS, United Kingdom
Phone: 44 1932 338303
Fax: 44 1932 338348
Email: j.fitzgerald@vmd.defra.gsi.gov.uk

Jack Kay
R&D Manager and Residues Advisor
Veterinary Medicines Directorate
Woodham Lane, New Naw,
Addlestone, Surrey  KT 15 3LS, United Kingdom
Phone: 44 1932 338323
Fax: 44 1932 336618
Email: j.kay@vmd.defra.gsi.gov.uk

UNITED STATES OF AMERICA/ETATS-UNIS D'AMÉRIQUE/ESTADOS UNIDOS DE AMÉRICA
Steven Vaughn
(Head of Delegation)
Food and Drug Administration
Center for Veterinary Medicine
7500 Standish Place
Rockville, MD 20855, United States
Phone: 301-827-1796
Fax: 301-594-2297
Email: svaughn@cvm.fda.gov

Alice Thaler
(Alternate Delegate)
USDA/FSIS
1400 Independence Ave , SW
343 Aerospace Center
Washington, DC 20250, United States
Phone: (202) 690-2687
Fax: (202) 720-8213
Email: alice.thaler@fsis.usda.gov

Steven Brynes
Food and Drug Administration
Center for Veterinary Medicine
7500 Standish Place
Rockville, MD 20855, United States
Phone: 301-827-6975
Fax: 301-594-2297
Email: sbrynes@cvm.fda.gov

Mary Carson
U.S. Food & Drug Administration
Office of Research, Center for Veterinary Medicine
8401 Muirkirk Road
Laurel, Maryland 20708, United States
Phone: 301-827-8169
Fax: 301-827-8170
Email: mcarson@cvm.fda.gov

Richard Coulter
Vice President, Scientific & Regulatory Affairs
Phibro Animal Health
710 Route 46 East
Suite 401
Fairfield, NJ 07004, United States
Phone: 973-439-4756
Fax: 973-244-5899
Email: Richard.Coulter@phibroah.com
Bernadette Dunham  
Food and Drug Administration  
Center for Veterinary Medicine  
Office of New Animal Drug Evaluation  
7500 Standish Place  
MPN II (HFV 100)  
Rockville, MD  20855, United States  
Phone: 301-827-0204  
Fax: 301-594-2297  
Email: Bernadette.Dunham@fda.hhs.gov

Paul Duquette  
Phibro Animal Health  
United States  
Phone: 973-439-4711  
Email: Paul.Duquette@phibroah.com

Richard Ellis  
Food and Drug Administration  
Center of Veterinary Medicine  
MPN-4 7519 Standish Place  
Rockville, MD  20855, United States  
Phone: 301-827-1416  
Fax: 301-594-2298  
Email: Richard.Ellis@fda.hhs.gov

Leslye Fraser  
Center for Food Safety and Applied Nutrition  
Food and Drug Administration  
5100 Paint Branch Highway  
College Park, Maryland  20740, United States  
Phone: 301-436-2378  
Email: Leslye.Fraser@cfsan.fda.gov

Elizabeth Curry-Galvin  
American Veterinary Medical Association  
1931 Meacham Road  
Suite 100  
Schaumburg, IL  60173-4360, United States  
Phone: 847-925-8070  
Fax: 847-925-9329  
Email: Egalvin@avma.org

Kevin Greenlees  
Food and Drug Administration  
Center for Veterinary Medicine  
Office of New Animal Drug Evaluation  
7500 Standish Place  
Rockville, Maryland  20855, United States  
Phone: 301-827-6977  
Fax: 301-594-2298  
Email: Kevin.Greenlees@fda.hhs.gov

John Horigan  
Phibro Animal Health  
United States  
Phone: 973-439-4701  
Email: John.Horigan@phibroah.com

Randall Huffman  
Vice President, Scientific Affairs  
American Meat Institute Foundation  
1700 N. Moore Street  
Suite 1600  
Arlington, VA  22209, United States  
Phone: 703-841-3659  
Fax: 703-527-0938  
Email: rhuffman@meatami.com

Philip Kijak  
Food and Drug Administration  
Office of Research  
8401 Muirkirk Road  
Laurel, MD  20708, United States  
Phone: 301-827-8166  
Fax: 301-827-8170  
Email: Pkijak@cvm.fda.gov

Robert Livingston  
Director  
International Affairs and Regulatory Policy  
Animal Health Institute  
1325 G Street, NW  
Washington, DC  20005-3104, United States  
Phone: 202-637-2440  
Fax: 202-393-1667  
Email: Rlivingston@ahi.org

Bruce Martin  
Manager  
Animal Health International Regulatory Affairs  
Elanco Animal Health  
2001 W. Main Street  
PO Box 708  
Greenfield, IN  46140, United States  
Phone: 317-277-5298  
Fax: 317-651-3850  
Email: Martin_Bruce_W@lilly.com
Michael McGowan
Director, Veterinary Medicine Regulatory Affairs
Pfizer Global Research and Development
Worldwide Strategic & Operations Management
Eastern Point Road
Mail Stop 8200-40
Groton, CT 06340, United States
Phone: 860-441-4947
Fax: 860-715-7670
Email: michael_j_mcgowan@groton.pfizer.com

C.W. McMillan
C.W. McMillan Co.
PO Box 1009
Alexandria, VA 22310, United States
Phone: 703-960-1982
Fax: 703-960-4976
Email: cwmco@aol.com

John O’Rangers
Analyticor, LLC
Consulting Services
PO Box 142
Adamstown, MD 21710-0142, United States
Phone: 301-874-5329
Fax: 301-874-5890
Email: blundi@starpower.net

Larry Stobbs
Director, Regulatory Affairs
Elanco Animal Health
2001 West Main Street
Greenfield, IN 46140, United States
Phone: 317-277-4087
Fax: 317-277-4962
Email: l.a.stobbs@lilly.com

Robin Woo
Center for Food Safety and Applied Nutrition
Food and Drug Administration
5100 Paint Branch Highway
College Park, MD 20740, United States
Phone: 301-436-2776
Email: Robin.Woo@fda.hhs.gov

Richard Wood
Executive Director
Food Animal Concerns Trust (FACT, Inc.)
P.O. Box 14599
Chicago, Illinois 60614, United States
Phone: 773-525-4952
Fax: 773-525-5226
Email: RRWood@FACT.cc

Penny Zervos
Chemist
USDA/FSIS
14th and Independence
Aerospace Center
Mail Drop 343
Washington, DC 20250, United States
Phone: 202-690-6168
Fax: 202-690-6565
Email: Penny.Zervos@usda.gov

INTERNATIONAL GOVERNMENTAL ORGANIZATIONS/ORGANISATIONS GOUVERNAMENTALES INTERNATIONALES/ORGANIZACIONES GUBERNAMENTALES INTERNACIONALES

FOOD AND AGRICULTURE ORGANIZATION OF THE UNITED NATIONS (FAO)/ORGANISATION DES NATIONS UNIES POUR L’ALIMENTATION ET L’AGRICULTURE/ORGANIZACIÓN DE LAS NACIONES UNIDAS PARA LA AGRICULTURA Y LA ALIMENTACIÓN

Maria de Lourdes Costarrica Gonzalez
Senior Officer
FAO
Viale delle Terme di Caracalla
Rome, 00100, Italy
Phone: +39 0657056060
Fax: +39 0657054593
Email: lourdes.costarrica@fao.org

Dieter Arnold
FAO Consultant
Frohnauer Strasse 8
Berlin, D-13467, Germany
Phone: 4930 404 7508
Fax: 4930 404 7508
Email: d.arnold@debitel.net

FAO/IAEA JOINT DIVISION

Alfredo Montes Nino
Consultant
IAEA
FAO/IAEA Agriculture and Biotechnology Laboratory
Seibesdorf, A-2444, Austria
Phone: +43 1 2600 28395
Fax: +43 1 2600 28222
Email: a.cannavan@iaea.org
WORLD HEALTH ORGANIZATION
(WHO)/ORGANISATION MONDIALE DE LA
SANTÉ (OMS)/ORGANIZACIÓN MUNDIAL
DE LA SALUD (OMS)

Angelika Tritscher
WHO/IPCS
20 Avenue Appia
CH 1211 Geneva 27, Switzerland
Phone: 41 22 791 35 69
Fax: 41 22 791 48 48
e-mail: tritschera@who.int

WORLD ORGANISATION FOR ANIMAL
HEALTH (OIE)/ORGANISATION MONDIAL
POUR LA SANTÉ ANIMAL/ORGANIZACIÓN
MUNDIAL DE SANIDAD ANIMAL

Patrick Dehaumont
Director AFSSA-ANVV
OIE
BP 90203 35302 Fougères, France
Phone: 33 0 2 99 94 7871
Fax: 33 0 2 99 94 7899
Email: p.dehaumont@anmv.afssa.fr

INTERNATIONAL NON-GOVERNMENTAL
ORGANIZATIONS/ORGANISATIONS NON-
GOUVERNEMENTALES
INTERNATIONALES/ORGANIZACIONES
INTERNACIONALES NO
GUBERNAMENTALES

BIOTECHNOLOGY INDUSTRY
ORGANIZATION

Janet Collins
Lead, Global Regulatory
Monsanto Company
1300 I (Eye) Street, NW
Suite 450 East
Washington, DC 20005, United States
Phone: 202-383-2861
Fax: 202-789-1748
Email: janet.e.collins@monsanto.com

CONSUMERS INTERNATIONAL

Carolyn Cairns
Senior Project Leader/Tech/Public Service Projects
Consumers Union
101 Truman Avenue
Yonkers, NY 10703-1057, United States
Phone: 914-378-2303
Fax: 914-378-2908
Email: cairca@consumer.org

Steven Roach
Food Safety Program Manager
Food Animal Concerns Trust
P.O. Box 14599
Chicago, IL 60614, United States
Phone: 515-232-2278
Fax: 815-301-1889
Email: saroach@fact.cc

David Wallinga
Food and Health Program Director
Institute for Agriculture and Trade Policy
2105 First Avenue South
Minneapolis, MN 55404, United States
Phone: 612-870-3418
Fax: 612-813-5612
Email: dwallinga@iatp.org

INSTITUTE OF FOOD TECHNOLOGISTS

Jennifer McEntire
Research Scientist
Institute of Food Technologists
1025 Connecticut Avenue, NW
5th Floor
Washington, DC 20036, United States
Phone: 202-466-5980
Fax: 202-466-5988
Email: jcmcentire@ift.org

Rosetta Newsome
Director, Science and Communication
Institute of Food Technologists
525 West Van Buren St., Suite 1000
Chicago, IL 60607, United States
Phone: 312-782-8424
Fax: 312-782-8348
Email: rlnewson@ift.org
INTERNATIONAL DAIRY FEDERATION (IDF)/FÉDÉRATION INTERNATIONAL DE LAITERIE (FIL)

Robin Condron
Manager Research and Development
Consumer and Market Assurance Division Dairy Australia
Locked Bag 104
Flinders Lane
Victoria, 8009, Australia
Phone: 61-3-9694-3831
Fax: 61-3-9694-3833
Email: rcondron@dairyaustralia.com.au

INTERNATIONAL FEDERATION FOR ANIMAL HEALTH

Espeisse Olivier
European Corporate Affairs Manager
IFAH
1 rue Defacqz
Brussels, 1000, Belgium
Phone: 0032 2548 8606
Email: espeisse_olivier@lilly.com

Richard Carnevale
Vice-President, Regulatory, Scientific & Internal Affairs
Animal Health Institute
1325 G Street, NW
Suite 700
Washington, DC 20005-3104, United States
Phone: 202-637-2440
Fax: 202-393-1667
Email: rcarnevale@ahi.org

Dennis Erpelding
Manager
Elanco Government Relations
Public Affairs and Communications
Elanco Animal Health
2001 West Main Street
P.O. Box 708
Greenfield, IN 46140, United States
Phone: 317-276-2721
Fax: 317-433-6353
Email: dle@lilly.com

David Gottschall
Associate Research Fellow
Department of Metabolism and Safety
Pfizer Animal Health
7000 Portage Road (0225-190-045)
Kalamazoo, MI 49001-0199, United States
Phone: 269-833-2466
Fax: 269-833-3302
Email: gottsd@pfizer.com

INTERNATIONAL CO-OPERATIVE ALLIANCE/ALLIANCE COOPÉRATIVE INTERNATIONALE/ALIANZA COOPERATIVA INTERNACIONAL

Kazuo Onitake
Safety Policy Service
Japanese Consumers' Co-operative Union
3-29-8, Shibuya, Shibuya-ku
Tokyo, 150-8913, Japan
Phone: +81-3-5778-8109
Fax: +81-3-5778-8002
Email: kazuo.onitake@jccu.co

LATINOAMERICAN POULTRY ASSOCIATION (ALA)/ASOCIACIÓN LATINOAMERICANA DE AVICULTURA

Ariel Mendes
Poultry Health ALA Committee Coordinator
ALA
Av. Brigadeiro Faria Lima 1912
12 andar - Conj. 12-A
Jardim Paulistano
Sao Paulo, CEP 01452-001, Brazil
Phone: 11 3812 7666
Fax: 11 3815 5964
Email: ubasp@uba.org.br

Marisite Cerutti
Quality Assurance Manager
ALA - Asociacion Latinoamericana de Avicultura
Av. Paludo, 155
Seara - SC, CEP 89.770-000, Brazil
Phone: 55-49-441-3072
Email: mcerutti@seara.com.br
SECRETARIAT/SECRETARIADO

JOINT FAO/WHO FOOD STANDARDS PROGRAMME/PROGRAMME MIXTE FAO/OMS SUR LES NORMES ALIMENTAIRES/PROGRAMMA CONJUNTO FAO/OMS SOBRE NORMAS ALIMENTARIAS

Annamaria Bruno
Food Standards Officer
Joint FAO/WHO Food Standards Programme
Viale delle Terme di Caracalla
Rome, 00100, Italy,
Phone: +39 06570 56254
Fax: +39 06570 54593
Email: annamaria.bruno@fao.org

Selma Doyran
Senior Food Standards Officer
FAO/WHO Joint Food Standards Programme
Vaile delle Terme Di Caracalla
Rome, 00100, Italy
Phone: +39 06 570 55826
Fax: +39 06 570 54593
Email: selma.doyran@fao.org

John Allan
Associate Food Standards Officer
Joint FAO/WHO Food Standards Programme
Viale delle Terme Di Caracalla
Rome, 00100, Italy
Phone: +39 06 570 53283
Fax: +39 06570 54593
Email: John.Allan@fao.org

UNITED STATES OF AMERICA/ETATS-UNIS D'AMÉRIQUE/ESTADOS UNIDOS DE AMÉRICA

Edith Kennard
Staff Officer
USDA/FSIS
Room 4865 South
1400 Independence Avenue SW
Washington, DC  20250, United States
Phone: 202-720-5261
Fax: 202-720-3157
Email: Edith.Kennard@fsis.usda.gov

Ellen Matten
Staff Officer
USDA/FSIS
Room 4865 South
1400 Independence Avenue, SW
Washington, DC  20250, United States
Phone: 202-720-4063
Fax: 202-720-3157
Email: ellen.matten@fsis.usda.gov

Marci Shaffer
IT Specialist
USDA/FSIS/AISD
Room 0137 South
1400 Independence Avenue, SW
Washington, DC  20250, United States
Phone: 202-720-4187
Fax: 202-690-6768
Email: marci.shaffer@fsis.usda.gov
DRAFT MAXIMUM RESIDUE LIMITS FOR VETERINARY DRUGS
(at Step 8 of the Elaboration Procedure)

Cyhalothrin

Acceptable Daily Intake: JECFA established a permanent ADI of 0-5 µg/kg bw.

Residue Definition: Cyhalothrin.

<table>
<thead>
<tr>
<th>Species</th>
<th>Tissue</th>
<th>MRLs(µg/kg)</th>
<th>Step</th>
<th>JECFA</th>
<th>CCRVDF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cattle</td>
<td>Muscle</td>
<td>20</td>
<td>8</td>
<td>54, 58, 62</td>
<td>13III, 26th CAC</td>
</tr>
<tr>
<td>Cattle</td>
<td>Liver</td>
<td>20</td>
<td>8</td>
<td>54, 58, 62</td>
<td>13III, 26th CAC</td>
</tr>
<tr>
<td>Cattle</td>
<td>Kidney</td>
<td>20</td>
<td>8</td>
<td>54, 58, 62</td>
<td>13III, 26th CAC</td>
</tr>
<tr>
<td>Cattle</td>
<td>Fat</td>
<td>400</td>
<td>8</td>
<td>54, 58, 62</td>
<td>13III, 26th CAC</td>
</tr>
<tr>
<td>Cattle</td>
<td>Milk</td>
<td>30</td>
<td>8</td>
<td>54, 58, 62</td>
<td>13III, 26th CAC</td>
</tr>
<tr>
<td>Pig</td>
<td>Muscle</td>
<td>20</td>
<td>8</td>
<td>54, 58, 62</td>
<td>13III, 26th CAC</td>
</tr>
<tr>
<td>Pig</td>
<td>Liver</td>
<td>20</td>
<td>8</td>
<td>54, 58, 62</td>
<td>13III, 26th CAC</td>
</tr>
<tr>
<td>Pig</td>
<td>Kidney</td>
<td>20</td>
<td>8</td>
<td>54, 58, 62</td>
<td>13III, 26th CAC</td>
</tr>
<tr>
<td>Pig</td>
<td>Fat</td>
<td>400</td>
<td>8</td>
<td>54, 58, 62</td>
<td>13III, 26th CAC</td>
</tr>
<tr>
<td>Sheep</td>
<td>Muscle</td>
<td>20</td>
<td>8</td>
<td>54, 58, 62</td>
<td>13III, 26th CAC</td>
</tr>
<tr>
<td>Sheep</td>
<td>Liver</td>
<td>50</td>
<td>8</td>
<td>54, 58, 62</td>
<td>13III, 26th CAC</td>
</tr>
<tr>
<td>Sheep</td>
<td>Kidney</td>
<td>20</td>
<td>8</td>
<td>54, 58, 62</td>
<td>13III, 26th CAC</td>
</tr>
<tr>
<td>Sheep</td>
<td>Fat</td>
<td>400</td>
<td>8</td>
<td>54, 58, 62</td>
<td>13III, 26th CAC</td>
</tr>
</tbody>
</table>

Keys for List of MRLs for Veterinary Drugs

Step: (r), revised MRL; (a), amended MRL.

JECFA: Meeting number of the Joint FAO/WHO Expert Committee on Food Additives where the MRL recommended/considered.

CCRVDF: Session number of the CCRVDF where the MRL was considered and Appendix number of its report where the MRL is contained.
**Flumequine**

**Acceptable Daily Intake:** JECFA re-established an ADI of 0-30 µg/kg bw.

**Residues:** Flumequine

<table>
<thead>
<tr>
<th>Species</th>
<th>Tissue</th>
<th>MRLs(µg/kg)</th>
<th>Step</th>
<th>JECFA</th>
<th>CCRVDF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cattle</td>
<td>Muscle</td>
<td>500</td>
<td>8</td>
<td>42, 48, 54, 62</td>
<td>11V,12IV,13IV,14IV</td>
</tr>
<tr>
<td>Cattle</td>
<td>Liver</td>
<td>500</td>
<td>8</td>
<td>42, 48, 54, 62</td>
<td>11V,12IV,13IV,14IV</td>
</tr>
<tr>
<td>Cattle</td>
<td>Kidney</td>
<td>3000</td>
<td>8</td>
<td>42, 48, 54, 62</td>
<td>11V,12IV,13IV,14IV</td>
</tr>
<tr>
<td>Cattle</td>
<td>Fat</td>
<td>1000</td>
<td>8</td>
<td>42, 48, 54, 62</td>
<td>11V,12IV,13IV,14IV</td>
</tr>
<tr>
<td>Chicken</td>
<td>Muscle</td>
<td>500</td>
<td>8</td>
<td>42, 48, 54, 62</td>
<td>11V,12IV,13IV,14IV</td>
</tr>
<tr>
<td>Chicken</td>
<td>Liver</td>
<td>500</td>
<td>8</td>
<td>42, 48, 54, 62</td>
<td>11V,12IV,13IV,14IV</td>
</tr>
<tr>
<td>Chicken</td>
<td>Kidney</td>
<td>3000</td>
<td>8</td>
<td>42, 48, 54, 62</td>
<td>11V,12IV,13IV,14IV</td>
</tr>
<tr>
<td>Chicken</td>
<td>Fat</td>
<td>1000</td>
<td>8</td>
<td>42, 48, 54, 62</td>
<td>11V,12IV,13IV,14IV</td>
</tr>
<tr>
<td>Pig</td>
<td>Muscle</td>
<td>500</td>
<td>8</td>
<td>42, 48, 54, 62</td>
<td>11V,12IV,13IV,14IV</td>
</tr>
<tr>
<td>Pig</td>
<td>Liver</td>
<td>500</td>
<td>8</td>
<td>42, 48, 54, 62</td>
<td>11V,12IV,13IV,14IV</td>
</tr>
<tr>
<td>Pig</td>
<td>Kidney</td>
<td>3000</td>
<td>8</td>
<td>42, 48, 54, 62</td>
<td>11V,12IV,13IV,14IV</td>
</tr>
<tr>
<td>Pig</td>
<td>Fat</td>
<td>1000</td>
<td>8</td>
<td>42, 48, 54, 62</td>
<td>11V,12IV,13IV,14IV</td>
</tr>
<tr>
<td>Sheep</td>
<td>Muscle</td>
<td>500</td>
<td>8</td>
<td>42, 48, 54, 62</td>
<td>11V,12IV,13IV,14IV</td>
</tr>
<tr>
<td>Sheep</td>
<td>Liver</td>
<td>500</td>
<td>8</td>
<td>42, 48, 54, 62</td>
<td>11V,12IV,13IV,14IV</td>
</tr>
<tr>
<td>Sheep</td>
<td>Kidney</td>
<td>3000</td>
<td>8</td>
<td>42, 48, 54, 62</td>
<td>11V,12IV,13IV,14IV</td>
</tr>
<tr>
<td>Sheep</td>
<td>Fat</td>
<td>1000</td>
<td>8</td>
<td>42, 48, 54, 62</td>
<td>11V,12IV,13IV,14IV</td>
</tr>
<tr>
<td>Trout</td>
<td>Muscle</td>
<td>500&lt;sup&gt;a&lt;/sup&gt;</td>
<td>8</td>
<td>42, 48, 54, 62</td>
<td>11V,12IV,13IV,14IV</td>
</tr>
</tbody>
</table>

<sup>a</sup> Muscle including normal proportion of skin.

**Neomycin**

**Acceptable Daily Intake:** The ADI of 0-60 µg/kg bw established at the 47<sup>th</sup> Meeting of the JECFA (WHO TRS 876, 1998) was maintained.

**Residue Definition:** Neomycin

<table>
<thead>
<tr>
<th>Species</th>
<th>Tissue</th>
<th>MRLs(µg/kg)&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Step</th>
<th>JECFA</th>
<th>CCRVDF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cattle</td>
<td>Liver</td>
<td>500</td>
<td>8</td>
<td>52, 58, 60</td>
<td>12V, 13IV, 14IV</td>
</tr>
<tr>
<td>Cattle</td>
<td>Kidney</td>
<td>10000</td>
<td>8</td>
<td>52, 58, 60</td>
<td>12V, 13IV, 14IV</td>
</tr>
<tr>
<td>Cattle</td>
<td>Milk</td>
<td>1500</td>
<td>8</td>
<td>52, 58, 60</td>
<td>12V, 13IV, 14IV</td>
</tr>
</tbody>
</table>

<sup>a</sup> The MRL of 500 µg/kg for cattle muscle and fat and all other MRLs recommended at the 47<sup>th</sup> meeting of the Committees were maintained.
**Diclofluanil**

**Acceptable Daily Intake:** 0-7 µg/kg bw (established at the 54th Meeting of the JECFA - WHO TRS 900, 2001).

**Residues:** Diclofluanil

<table>
<thead>
<tr>
<th>Species</th>
<th>Tissue</th>
<th>MRLs(µg/kg)</th>
<th>Step</th>
<th>JECFA</th>
<th>CCRVDF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sheep</td>
<td>Muscle</td>
<td>150</td>
<td>8</td>
<td>54, 60</td>
<td>13V, 14IV</td>
</tr>
<tr>
<td>Sheep</td>
<td>Liver</td>
<td>125</td>
<td>8</td>
<td>54, 60</td>
<td>13V, 14IV</td>
</tr>
<tr>
<td>Sheep</td>
<td>Kidney</td>
<td>125</td>
<td>8</td>
<td>54, 60</td>
<td>13V, 14IV</td>
</tr>
<tr>
<td>Sheep</td>
<td>Fat</td>
<td>200</td>
<td>8</td>
<td>54, 60</td>
<td>13V, 14IV</td>
</tr>
</tbody>
</table>

---

**Keys for List of MRLs for Veterinary Drugs**

**Step:** (r), revised MRL; (a), amended MRL.

**JECFA:** Meeting number of the Joint FAO/WHO Expert Committee on Food Additives where the MRL recommended/considered.

**CCRVDF:** Session number of the CCRVDF where the MRL was considered and Appendix number of its report where the MRL is contained.
PROPOSED DRAFT MAXIMUM RESIDUE LIMITS FOR VETERINARY DRUGS
(Advanced to Steps 5/8 of the Elaboration Procedure)

**Imidocarb**

Acceptable Daily Intake: 0-10 µg/kg bw (established at the 50th Meeting of JECFA - WHO TRS 888, 1999).

Residues: Imidocarb free base

<table>
<thead>
<tr>
<th>Species</th>
<th>Tissue</th>
<th>MRLs(µg/kg)</th>
<th>Step</th>
<th>JECFA</th>
<th>CCRVDF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cattle</td>
<td>Muscle</td>
<td>300</td>
<td>5/8</td>
<td>60</td>
<td></td>
</tr>
<tr>
<td>Cattle</td>
<td>Liver</td>
<td>1500</td>
<td>5/8</td>
<td>60</td>
<td></td>
</tr>
<tr>
<td>Cattle</td>
<td>Kidney</td>
<td>2000</td>
<td>5/8</td>
<td>60</td>
<td></td>
</tr>
<tr>
<td>Cattle</td>
<td>Fat</td>
<td>50</td>
<td>5/8</td>
<td>60</td>
<td></td>
</tr>
<tr>
<td>Cattle</td>
<td>Milk</td>
<td>50</td>
<td>5/8</td>
<td>60</td>
<td></td>
</tr>
</tbody>
</table>

---

Keys for List of MRLs for Veterinary Drugs

Step: (r), revised MRL; (a), amended MRL.

JECFA: Meeting number of the Joint FAO/WHO Expert Committee on Food Additives where the MRL recommended/considered.

CCRVDF: Session number of the CCRVDF where the MRL was considered and Appendix number of its report where the MRL is contained.
DRAFT MAXIMUM RESIDUE LIMITS FOR VETERINARY DRUGS
(at Step 7 of the Elaboration Procedure)

Trichlorfon (Metrifonate)

Acceptable Daily Intake: JECFA amended the ADI for trichlorfon from 0-20 µg/kg to 0-2 µg/kg bw.

Residues: JECFA confirmed the MRL for cows’s milk and the guidance levels for muscle, liver, kidney and fat of cattle recommended at the 54th meeting (WHO TRS 900, 2001).

<table>
<thead>
<tr>
<th>Species</th>
<th>Tissue</th>
<th>MRL (µg/kg)</th>
<th>Step</th>
<th>JECFA</th>
<th>CCRVDF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cattle</td>
<td>Milk</td>
<td>50 T</td>
<td>(retained at) 7</td>
<td>54, 60</td>
<td>13 V, 14IV</td>
</tr>
</tbody>
</table>

Keys for List of MRLs for Veterinary Drugs

Step: (r), revised MRL; (a), amended MRL.

JECFA: Meeting number of the Joint FAO/WHO Expert Committee on Food Additives where the MRL recommended/considered.

CCRVDF: Session number of the CCRVDF where the MRL was considered and Appendix number of its report where the MRL is contained.
PROPOSED DRAFT MAXIMUM RESIDUE LIMITS FOR VETERINARY DRUGS
(at Step 5 of the Elaboration Procedure)

**Flumequine**

**Acceptable Daily Intake:** 0-30 µg/kg body weight (1997)

**Residue Definition:** Flumequine.

<table>
<thead>
<tr>
<th>Species</th>
<th>Tissue</th>
<th>MRL (µg/kg)</th>
<th>Step</th>
<th>JECFA</th>
<th>CCRVDF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Black tiger shrimp (<em>P. monodon</em>)</td>
<td>Muscle</td>
<td>500 T&lt;sup&gt;a&lt;/sup&gt;</td>
<td>5</td>
<td>62</td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup> The MRL is temporary; the following information is requested by 2006: (1) A detailed description of a regulatory method, including its performance characteristics and validation data; (2) Information on the approved dose for treatment of black tiger shrimp and the results of the residue studies conducted at the recommended dose.

**Pirlimycin**

**Acceptable Daily Intake:** JECFA established an ADI of 0-8 µg/kg bw.

**Residues:** Pirlimycin

<table>
<thead>
<tr>
<th>Species</th>
<th>Tissue</th>
<th>MRLs(µg/kg)</th>
<th>Step</th>
<th>JECFA</th>
<th>CCRVDF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cattle</td>
<td>Muscle</td>
<td>100</td>
<td>5</td>
<td>62</td>
<td></td>
</tr>
<tr>
<td>Cattle</td>
<td>Liver</td>
<td>1000</td>
<td>5</td>
<td>62</td>
<td></td>
</tr>
<tr>
<td>Cattle</td>
<td>Kidney</td>
<td>400</td>
<td>5</td>
<td>62</td>
<td></td>
</tr>
<tr>
<td>Cattle</td>
<td>Fat</td>
<td>100</td>
<td>5</td>
<td>62</td>
<td></td>
</tr>
<tr>
<td>Cattle</td>
<td>Milk</td>
<td>100</td>
<td>5</td>
<td>62</td>
<td></td>
</tr>
</tbody>
</table>
### Cypermethrin and alpha-cypermethrin

**Acceptable Daily Intake:** JECFA established a common ADI of 0-20 µg/kg bw for both cypermethrin and alpha-cypermethrin.

**Residues:** Total of cypermethrin residues (resulting from the use of cypermethrin or alpha-cypermethrin as veterinary drugs).

<table>
<thead>
<tr>
<th>Species</th>
<th>Tissue</th>
<th>MRLs(µg/kg)</th>
<th>Step</th>
<th>JECFA</th>
<th>CCRVDF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cattle</td>
<td>Muscle</td>
<td>50</td>
<td>5</td>
<td>62</td>
<td></td>
</tr>
<tr>
<td>Cattle</td>
<td>Liver</td>
<td>50</td>
<td>5</td>
<td>62</td>
<td></td>
</tr>
<tr>
<td>Cattle</td>
<td>Kidney</td>
<td>50</td>
<td>5</td>
<td>62</td>
<td></td>
</tr>
<tr>
<td>Cattle</td>
<td>Fat</td>
<td>1000</td>
<td>5</td>
<td>62</td>
<td></td>
</tr>
<tr>
<td>Cattle</td>
<td>Milk</td>
<td>100</td>
<td>5</td>
<td>62</td>
<td></td>
</tr>
<tr>
<td>Sheep</td>
<td>Muscle</td>
<td>50</td>
<td>5</td>
<td>62</td>
<td></td>
</tr>
<tr>
<td>Sheep</td>
<td>Liver</td>
<td>50</td>
<td>5</td>
<td>62</td>
<td></td>
</tr>
<tr>
<td>Sheep</td>
<td>Kidney</td>
<td>50</td>
<td>5</td>
<td>62</td>
<td></td>
</tr>
<tr>
<td>Sheep</td>
<td>Fat</td>
<td>1000</td>
<td>5</td>
<td>62</td>
<td></td>
</tr>
</tbody>
</table>

### Doramectin

**Acceptable Daily Intake:** 0-1 µg/kg bw (established at the 58th meeting, WHO TRS 911, 2002).

**Residues:** Doramectin.

<table>
<thead>
<tr>
<th>Species</th>
<th>Tissue</th>
<th>MRLs(µg/kg)</th>
<th>Step</th>
<th>JECFA</th>
<th>CCRVDF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cattle</td>
<td>Milk</td>
<td>15&lt;sup&gt;a&lt;/sup&gt;</td>
<td>5</td>
<td>62</td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup> JECFA noted that (1) on the basis of a 15 µg/kg MRL for doramectin in whole milk in cattle, the milk discard times would be approximately 240 hours based on the studies using the pour-on treatment. Milk discard times would be approximately 480 hours following treatment using the injection formulated dose; (2) in milk containing 4 per cent milk fat, the residues in milk would be equivalent to 375 µg/kg (15 µg/kg ÷ 0.04 = 375 µg/kg). This is higher than the 150 µg/kg MRL in fat tissue; (3) the discard time necessary to accommodate the recommended MRL in milk is unlikely to be consistent with good veterinary practice.

---

**Keys for List of MRLs for Veterinary Drugs**

**Step:** (r), revised MRL; (a), amended MRL.

**JECFA:** Meeting number of the Joint FAO/WHO Expert Committee on Food Additives where the MRL recommended/considered.

**CCRVDF:** Session number of the CCRVDF where the MRL was considered and Appendix number of its report where the MRL is contained.
PROPOSED DRAFT MAXIMUM RESIDUE LIMITS FOR VETERINARY DRUGS
(at Step 4 of the Elaboration Procedure)

**Ractopamine**

Acceptable Daily Intake: 0-1 µg/kg bw.

Residues: Ractopamine

<table>
<thead>
<tr>
<th>Species</th>
<th>Tissue</th>
<th>MRLs(µg/kg)</th>
<th>Step</th>
<th>JECFA</th>
<th>CCRVDF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cattle</td>
<td>Muscle</td>
<td>10</td>
<td>4</td>
<td>62</td>
<td></td>
</tr>
<tr>
<td>Cattle</td>
<td>Liver</td>
<td>40</td>
<td>4</td>
<td>62</td>
<td></td>
</tr>
<tr>
<td>Cattle</td>
<td>Kidney</td>
<td>90</td>
<td>4</td>
<td>62</td>
<td></td>
</tr>
<tr>
<td>Cattle</td>
<td>Fat</td>
<td>10</td>
<td>4</td>
<td>62</td>
<td></td>
</tr>
<tr>
<td>Pig</td>
<td>Muscle</td>
<td>10</td>
<td>4</td>
<td>62</td>
<td></td>
</tr>
<tr>
<td>Pig</td>
<td>Liver</td>
<td>40</td>
<td>4</td>
<td>62</td>
<td></td>
</tr>
<tr>
<td>Pig</td>
<td>Kidney</td>
<td>90</td>
<td>4</td>
<td>62</td>
<td></td>
</tr>
<tr>
<td>Pig</td>
<td>Fat</td>
<td>10</td>
<td>4</td>
<td>62</td>
<td></td>
</tr>
</tbody>
</table>

---

Keys for List of MRLs for Veterinary Drugs

Step: (r), revised MRL; (a), amended MRL.

JECFA: Meeting number of the Joint FAO/WHO Expert Committee on Food Additives where the MRL recommended/considered.

CCRVDF: Session number of the CCRVDF where the MRL was considered and Appendix number of its report where the MRL is contained.
DISCONTINUED WORK ON DRAFT AND PROPOSED DRAFT MAXIMUM RESIDUE LIMITS FOR VETERINARY DRUGS

**Phoxim**
**Acceptable Daily Intake:** 0-4 µg/kg bw (established at the 52nd Meeting of JECFA - WHO TRS 893, 2000).

**Residue Definition:** Phoxim.

<table>
<thead>
<tr>
<th>Species</th>
<th>Tissue</th>
<th>MRLs(µg/kg)</th>
<th>Step</th>
<th>JECFA</th>
<th>CCRVDF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cattle</td>
<td>Muscle</td>
<td>50 T</td>
<td>6</td>
<td>52, 58</td>
<td>12V, 13II, 26th CAC</td>
</tr>
<tr>
<td>Cattle</td>
<td>Liver</td>
<td>50 T</td>
<td>6</td>
<td>52, 58</td>
<td>12V, 13II, 26th CAC</td>
</tr>
<tr>
<td>Cattle</td>
<td>Kidney</td>
<td>50 T</td>
<td>6</td>
<td>52, 58</td>
<td>12V, 13II, 26th CAC</td>
</tr>
<tr>
<td>Cattle</td>
<td>Fat</td>
<td>400 T</td>
<td>6</td>
<td>52, 58</td>
<td>12V, 13II, 26th CAC</td>
</tr>
<tr>
<td>Cattle</td>
<td>Milk</td>
<td>10 T</td>
<td>6</td>
<td>52, 58</td>
<td>12V, 13II, 26th CAC</td>
</tr>
</tbody>
</table>

**Cefuroxime**
**Acceptable Daily Intake:** The temporary ADI established at the 58th Meeting of JECFA (WHO TRS 911, 2002) was withdrawn.

**Residues:** The temporary MRL for cattle milk was withdrawn.

<table>
<thead>
<tr>
<th>Species</th>
<th>Tissue</th>
<th>MRLs(µg/kg)</th>
<th>Step</th>
<th>JECFA</th>
<th>CCRVDF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cattle</td>
<td>Milk</td>
<td>50 T</td>
<td>5</td>
<td>58</td>
<td>14IV</td>
</tr>
</tbody>
</table>

Keys for List of MRLs for Veterinary Drugs

**Step:** (r), revised MRL; (a), amended MRL.

**JECFA:** Meeting number of the Joint FAO/WHO Expert Committee on Food Additives where the MRL recommended/considered.

**CCRVDF:** Session number of the CCRVDF where the MRL was considered and Appendix number of its report where the MRL is contained.
### Cypermethrin

**ADI:** 0 - 50 µg/kg body weight (1996)  
**Residue Definition:** Cypermethrin

<table>
<thead>
<tr>
<th>Species</th>
<th>Tissue</th>
<th>MRL (µg/kg)</th>
<th>Step</th>
<th>JECFA</th>
<th>CCRVDF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sheep</td>
<td>Muscle</td>
<td>20</td>
<td>4</td>
<td>58</td>
<td></td>
</tr>
<tr>
<td>Sheep</td>
<td>Liver</td>
<td>20</td>
<td>4</td>
<td>58</td>
<td></td>
</tr>
<tr>
<td>Sheep</td>
<td>Kidney</td>
<td>20</td>
<td>4</td>
<td>58</td>
<td></td>
</tr>
<tr>
<td>Sheep</td>
<td>Fat</td>
<td>200</td>
<td>4</td>
<td>58</td>
<td></td>
</tr>
</tbody>
</table>

- The ADI established at 47th JECFA was for a 45:55 cis:trans mixture. Information provided to the Committee at the 58th JECFA was for a 80:20 cis:trans mixture for topical use. Because the cis isomer is more toxic than the trans isomer, the Committee compared the theoretical maximum daily intake for the 80:20 cis:trans mixture with the ADI for alpha-cypermethrin, which consists only of the cis isomer.

### alpha-Cypermethrin

**ADI:** 0 - 20 µg/kg body weight (1996)  
**Residue Definition:** alpha-Cypermethrin

<table>
<thead>
<tr>
<th>Species</th>
<th>Tissue</th>
<th>MRL (µg/kg)</th>
<th>Step</th>
<th>JECFA</th>
<th>CCRVDF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cattle</td>
<td>Muscle</td>
<td>100</td>
<td>4</td>
<td>58</td>
<td></td>
</tr>
<tr>
<td>Cattle</td>
<td>Liver</td>
<td>100</td>
<td>4</td>
<td>58</td>
<td></td>
</tr>
<tr>
<td>Cattle</td>
<td>Kidney</td>
<td>100</td>
<td>4</td>
<td>58</td>
<td></td>
</tr>
<tr>
<td>Cattle</td>
<td>Fat</td>
<td>1000</td>
<td>4</td>
<td>58</td>
<td></td>
</tr>
<tr>
<td>Cattle</td>
<td>Milk</td>
<td>100</td>
<td>4</td>
<td>58</td>
<td></td>
</tr>
<tr>
<td>Sheep</td>
<td>Muscle</td>
<td>100</td>
<td>4</td>
<td>58</td>
<td></td>
</tr>
<tr>
<td>Sheep</td>
<td>Liver</td>
<td>100</td>
<td>4</td>
<td>58</td>
<td></td>
</tr>
<tr>
<td>Sheep</td>
<td>Kidney</td>
<td>100</td>
<td>4</td>
<td>58</td>
<td></td>
</tr>
<tr>
<td>Sheep</td>
<td>Fat</td>
<td>1000</td>
<td>4</td>
<td>58</td>
<td></td>
</tr>
</tbody>
</table>
PROPOSED DRAFT CODE OF PRACTICE TO MINIMIZE AND CONTAIN ANTIMICROBIAL RESISTANCE
(at Steps 5/8 of the Elaboration Procedure)

Table of Contents ............................................................................................................. 1
INTRODUCTION ............................................................................................................................. 2
AIMS AND OBJECTIVES ............................................................................................................... 2
RESPONSIBILITIES OF THE REGULATORY AUTHORITIES .............................................................. 4
Quality Control of veterinary antimicrobial drugs ................................................................. 5
Assessment of efficacy ........................................................................................................... 5
Assessment of the potential of veterinary antimicrobial drugs to select for resistant microorganisms .................................................................................................................. 6
Establishment of ADIs (acceptable daily intake). MRLs (maximum residue limit), and Withdrawal periods for veterinary antimicrobial drugs ............................................................................................................. 6
Establishment of a summary of product characteristics for each veterinary antimicrobial drug for food-producing animals ........................................................................................................... 7
Surveillance programmes ...................................................................................................... 7
Distribution of the veterinary antimicrobial drugs in veterinary medicine ................................ 8
Control of advertising ........................................................................................................... 8
Training of veterinary antimicrobial drug users ..................................................................... 8
Development of research ..................................................................................................... 9
Collection and destruction of unused products and container .............................................. 9
RESPONSIBILITIES OF THE VETERINARY PHARMACEUTICAL INDUSTRY ...................................... 9
Marketing authorisation of veterinary antimicrobial drugs for food-producing animals ........ 9
Marketing and export of veterinary antimicrobial drugs ....................................................... 9
Advertising ............................................................................................................................. 9
Training .................................................................................................................................. 10
Research ............................................................................................................................... 10
RESPONSIBILITIES OF WHOLESALE AND RETAIL DISTRIBUTORS ................................................. 10
RESPONSIBILITIES OF VETERINARIANS ............................................................................................... 10
Off-label use .......................................................................................................................... 11
Recording ............................................................................................................................. 12
Training ............................................................................................................................... 12
RESPONSIBILITIES OF PRODUCERS ....................................................................................................... 12
CONCLUSIONS .................................................................................................................................. 13
Endnotes ....................................................................................................................................... 13
List of Abbreviations ............................................................................................................... 14
Glossary and Definitions of Terms .......................................................................................... 15
INTRODUCTION

1. This document provides additional guidance for the responsible and prudent use of antimicrobials in food-producing animals, and should be read in conjunction with the Recommended International Code of Practice for Control of the Use of Veterinary Drugs CAC/RCP 38-1993. Its objectives are to minimize the potential adverse impact on public health resulting from the use of antimicrobial agents in food-producing animals, in particular the development of antimicrobial resistance. It is also important to provide for the safe and effective use of veterinary antimicrobial drugs in veterinary medicine by maintaining their efficacy. This document defines the respective responsibilities of authorities and groups involved in the authorization, production, control, distribution and use of veterinary antimicrobials such as the national regulatory authorities, the veterinary pharmaceutical industry, veterinarians, distributors and producers of food-producing animals.

2. The marketing authorization procedure has a significant role in establishing the basis for prudent use of veterinary antimicrobial drugs in food-producing animals through clear label indications, directions and warning statements.

3. A number of codes of practice relating to the use of veterinary antimicrobial drugs and the conditions thereof have been developed by different organisations. These codes were taken into consideration and some elements were included in the elaboration of this Code of Practice to Minimize and Contain Antimicrobial Resistance.

4. In keeping with the Codex mission, this Code focuses on antimicrobial use in food–producing animals. It is recognized that antimicrobial resistance is also an ecological problem and that management of antimicrobial resistance may require addressing the persistence of resistant microorganisms in the environment. Although this issue is most relevant for CCRVDF with respect to food-producing animals, the same principles apply to companion animals, which also harbor resistant microorganisms.

AIMS AND OBJECTIVES

5. It is imperative that all who are involved in the authorisation, manufacture, sale and supply, prescription and use of antimicrobials in food-producing animals act legally, responsibly and with the utmost care in order to limit the spread of resistant microorganisms among animals so as to protect the health of consumers.

6. Antimicrobial drugs are powerful tools for the management of infectious diseases in animals and humans. This Code and existing guidelines for the responsible use of antimicrobial drugs in food-producing animals include recommendations intended to prevent or reduce the selection of antimicrobial resistant microorganisms in animals and humans in order to:

   • Protect consumer health by ensuring the safety of food of animal origin intended for human consumption.
   • Prevent or reduce as far as possible the direct and indirect transfer of resistant microorganisms or resistance determinants within animal populations and from food-producing animals to humans.
   • Prevent the contamination of animal derived food with antimicrobial residues which exceed the established MRL.
   • Comply with the ethical obligation and economic need to maintain animal health.
7. This Code does not address environmental issues related to antimicrobial resistance from the use of veterinary antimicrobial drugs but it encourages all those involved to consider the ecological aspects when implementing the Code. Efforts should be made to ensure that environmental reservoirs of veterinary antimicrobial drugs, antimicrobial resistant organisms and resistance determinants are kept to a minimum. In particular:

- Regulatory authorities should assess the impact of proposed veterinary antimicrobial drug use on the environment in accordance with national guidelines or recognized international guidelines\(^1\).
- Research should be conducted on resistant microorganisms in the environment and the magnitude of resistance determinant transfer among microorganisms in the environment.

8. The responsible use of veterinary antimicrobial drugs in food-producing animals:

- is controlled by the veterinary profession or other parties with the required expertise.
- is part of good veterinary and good animal husbandry practice and takes into consideration disease prevention practices such as the use of vaccination and improvements in husbandry conditions.
- aims to limit the use of veterinary antimicrobial drugs according to their approved and intended uses, and takes into consideration on-farm sampling and testing of isolates from food-producing animals during their production, where appropriate, and makes adjustments to treatment when problems become evident.
- should be based on the results of resistance surveillance and monitoring (microbial cultures and antimicrobial sensitivity testing), as well as clinical experience.
- does not include the use for growth promotion of veterinary antimicrobial drugs that belong to or are able to cause cross resistance to classes of antimicrobial agents used (or submitted for approval) in humans in the absence of a risk analysis. This risk analysis should:
  - be undertaken by the appropriate national regulatory authority
  - be based on adequate scientific evidence and
  - focus on the potential to impact resistance to antimicrobials used in human medicine.
- is aimed at all the relevant parties, such as:
  - regulatory and scientific authorities
  - the veterinary pharmaceutical industry
  - distributors and others handling veterinary antimicrobial drugs
  - veterinarians, pharmacists and producers of food-producing animals

\(^{1}\) VICH (2000). Guidelines on Environmental Impact Assessment for Veterinary Medicinal Products, Phase I.
RESPONSIBILITIES OF THE REGULATORY AUTHORITIES

9. The national regulatory authorities, which are responsible for granting the marketing authorisation for antimicrobials for use in food-producing animals, have a significant role in specifying the terms of this authorisation and in providing the appropriate information to the veterinarian through product labelling and/or by other means, in support of prudent use of veterinary antimicrobial drugs in food-producing animals. It is the responsibility of regulatory authorities to develop up-to-date guidelines on data requirements for evaluation of veterinary antimicrobial drug applications. National governments in cooperation with animal and public health professionals should adopt a proactive approach to promote prudent use of antimicrobials in food-producing animals as an element of a national strategy for the containment of antimicrobial resistance. Other elements of the national strategy should include good animal husbandry practices, vaccination policies and development of animal health care at the farm level, all of which should contribute to reduce the prevalence of animal disease requiring antimicrobial treatment. Use of veterinary antimicrobial drugs for growth promotion that belong to classes of antimicrobial agents used (or submitted for approval) in humans and animals should be terminated or phased out in the absence of risk-analysis, as described in Paragraph 8.

10. It is the responsibility of the pharmaceutical company or sponsor\(^2\) to submit the data requested by the regulatory authorities for granting marketing authorisation.

11. The use of antimicrobial agents in food-producing animals requires a marketing authorisation, granted by the competent authorities when the criteria of safety, quality and efficacy are met.

- The examination of dossiers/drug applications should include an assessment of the risks to both animals and humans resulting from the use of antimicrobial agents in food-producing animals. The evaluation should focus on each individual veterinary antimicrobial drug but take into consideration the class of antimicrobials to which the particular active principle belongs.

- The safety evaluation should include consideration of the potential impact of the proposed use in food-producing animals on human health, including the human health impact of antimicrobial resistance developing in microorganisms found in food-producing animals and their environment associated with the use of veterinary antimicrobial drugs.

12. If dose ranges or different durations of treatment are indicated, the national authorities should give guidance on the approved product labelling regarding the conditions that will minimize the development of resistance, when this information is available.

13. The relevant authorities should make sure that all the antimicrobial agents used in food-producing animals are prescribed by a veterinarian or other suitably trained person authorized in accordance with national legislation or used under conditions stipulated in the national legislation. (See OIE Guidelines for Antimicrobial Resistance: Responsible and Prudent Use of Antimicrobial Agents in Veterinary Medicine (Terrestrial Animal Health Code, Appendix 3.9.3)

14. No veterinary antimicrobial drug should be administered to animals unless it has been evaluated and authorized for such use by the relevant authorities or the use is allowed through off-label guidance or legislation. Regulatory authorities should, where possible, expedite the market approval process of new veterinary antimicrobial drug formulations considered to have the potential to make an important contribution in the control of antimicrobial resistance.

15. Countries without the necessary resources to implement an efficient authorisation procedure for veterinary antimicrobial drugs and whose supply of veterinary antimicrobial drugs mostly depends on imports from foreign countries should:

- ensure the efficacy of their administrative controls on the import of these veterinary antimicrobial drugs,
- seek information on authorizations valid in other countries, and
- develop the necessary technical cooperation with experienced authorities to check the quality of imported veterinary antimicrobial drugs as well as the validity of the recommended conditions of use. Alternatively, a national authority could delegate a competent institution to provide quality certification of veterinary antimicrobial drugs.

16. All countries should make every effort to actively combat the manufacture, advertisement, trade, distribution and use of illegal and/or counterfeit bulk active pharmaceutical ingredients and products. Regulatory authorities of importing countries could request the pharmaceutical industry to provide quality certificates or, where feasible, certificates of Good Manufacturing Practices prepared by the exporting country’s national regulatory authority.

**Quality Control of Antimicrobial Agents**

17. Regulatory authorities should ensure that quality controls are carried out in accordance with international guidance and in compliance with the provisions of good manufacturing practices, in particular:

- to ensure that the quality and concentration (stability) of veterinary antimicrobial drugs in the marketed dosage form(s) is maintained and properly stored up to the expiry date, established under the recommended storage conditions.
- to ensure the stability of veterinary antimicrobial drugs when they are mixed with feed or drinking water.
- to ensure that all veterinary antimicrobial drugs are manufactured to the appropriate quality and purity.

**Assessment of Efficacy**

18. Preclinical data should be generated to establish an appropriate dosage regimen necessary to ensure the efficacy of the veterinary antimicrobial drug and limit the selection of microbial resistant microorganisms. Such preclinical trials should, where applicable, include pharmacokinetic and pharmacodynamic studies to guide the development of the most appropriate dosage regimen.

19. Important pharmacodynamic information may include:

- mode of action;
- the spectrum of antimicrobial activity of the substance;
- identification of bacterial species that are naturally resistant relevant to the use of the veterinary antimicrobial drugs;
- antimicrobial minimum inhibitory and/or bactericidal concentrations;
- determination of whether the antimicrobial exhibits time or concentration-dependent activity or co-dependency,
- evaluation of activity at the site of infection.
20. Important pharmacokinetic information may include:
   - bio-availability according to the route of administration;
   - concentration of the veterinary antimicrobial drug at the site of infection and its distribution in the treated animal;
   - metabolism which may lead to the inactivation of veterinary antimicrobial drugs;
   - excretion routes.

21. The use of fixed combinations of veterinary antimicrobial drugs should be justified taking into account:
   - pharmacodynamic (additive or synergistic effects towards the target microorganism);
   - pharmacokinetics (maintenance of the concentrations of associated antimicrobials responsible for additive or synergistic effects at the site of infection throughout the treatment period).

22. Clinical data should be generated to confirm the validity of the claimed indications and dosage regimens established during the preclinical phase.

23. Criteria to be considered include:
   - parameters for qualitatively and quantitatively assessing efficacy;
   - diversity of the clinical cases met when carrying out clinical trials;
   - compliance of the protocols of clinical trials with good clinical practice, such as VICH guidelines;
   - eligibility of the studied clinical cases based on appropriate clinical and microbiological criteria.

**Assessment of the potential of veterinary antimicrobial drugs to select for resistant microorganisms**

24. Where applicable, data from preclinical or clinical trials should be used to evaluate the potential for target microorganisms, foodborne and/or commensal microorganisms to develop or acquire resistance.

25. Appropriate information should be provided to support an adequate assessment of the safety of veterinary antimicrobial drugs being considered for authorisation in food-producing animals. The regulatory authorities should develop criteria for conducting such assessments and interpreting their results. Existing guidelines for antimicrobial resistance risk assessment, such as the OIE Guideline may be used for more comprehensive information. The type of information to be evaluated in these assessments may include, but is not limited to, the following:
   - the route and level of human exposure to food-borne or other resistant organisms;
   - the degree of cross resistance within the class of antimicrobials and between classes of antimicrobials;
   - the pre-existing level of resistance, if available, in pathogens causing gastrointestinal infections in humans (baseline determination);
   - the concentration of active compound in the gut of the animal at the defined dosage level.

**Establishment of ADIs (acceptable daily intake), MRLs (maximum residue limit), and withdrawal periods for veterinary antimicrobial drugs**

26. When setting ADIs and MRLs for veterinary antimicrobial drugs, the safety evaluation is carried out in accordance with international guidelines and should include the determination of microbiological effects (e.g., the potential biological effects on the human intestinal flora) as well as toxicological and pharmacological effects.

---

4 Antimicrobial resistance: risk analysis methodology for the potential impact on public health of antimicrobial resistant bacteria of animal origin, [http://www.oie.int/eng/publicat/rt/2003a_r20314.htm](http://www.oie.int/eng/publicat/rt/2003a_r20314.htm)
27. An acceptable daily intake (ADI) and a maximum residue limit (MRL) for appropriate food stuffs (i.e., meat, milk, eggs, fish and honey) should be established for each antimicrobial agent. MRLs are necessary in order that officially recognised control laboratories can monitor that the veterinary antimicrobial drugs are being used as approved. Withdrawal periods should be established for each veterinary antimicrobial drug, which make it possible to produce food in compliance with the MRLs.

28. Withdrawal periods have to be established for each veterinary antimicrobial drug by taking into account:
   - the MRLs established for the considered veterinary antimicrobial drug;
   - the pharmaceutical form;
   - the target animal species;
   - the dosage regimen and the duration of treatment;
   - the route of administration.

**Establishment of a summary of product characteristics for each veterinary antimicrobial drug for food-producing animals**

29. The summary of product characteristics contains the information necessary for the appropriate use of veterinary antimicrobial drugs. It constitutes, for each veterinary antimicrobial drug, the official reference of the content of its labelling and package insert. This summary contains the following items:
   - pharmacological properties;
   - target animal species;
   - indications;
   - target microorganisms;
   - dosage and administration route;
   - withdrawal periods;
   - incompatibilities;
   - shelf-life;
   - operator safety;
   - particular precautions before use;
   - instructions for the return or proper disposal of un-used or out-of-date products;
   - any information on conditions of use relevant to the potential for selection of resistance should be included, for the purpose of guidance on prudent use;
   - class and active ingredient of the veterinary antimicrobial drug.

**Surveillance Programmes**

30. The relevant authorities should develop a structured approach to the investigation and reporting of the incidence and prevalence of antimicrobial resistance. For the purposes of this Code, priority should be given to the evaluation of antimicrobial resistance in foodborne microorganisms.

   For reasons of efficiency, the methods used to establish such programmes (laboratory techniques, sampling, choice of veterinary antimicrobial drug(s) and microorganism(s)) should be harmonized as much as possible at the international level (e.g. OIE documents on “Harmonisation of National Antimicrobial Resistance Monitoring and Surveillance Programmes in Animals and Animal Derived Food” [http://www.oie.int/eng/publicat/rt/2003/a_r20318.htm] and “Standardisation and Harmonisation of Laboratory Methodologies Used for the Detection and Quantification of Antimicrobial Resistance” [http://www.oie.int/eng/publicat/rt/2003/a_r20317.htm]).
31. Preferably, epidemiological surveillance of antimicrobial resistance should be accompanied by data on the amounts of veterinary antimicrobial drugs used by veterinarians and other authorized users in food-producing animals. These data could be collected using one or more of the following sources:

- production data from manufacturers;
- importers and exporters;
- if possible, data on intended and actual usage from manufacturers, wholesale and retail distributors including feed mills, and veterinary prescription records;
- surveys of veterinarians, farmers and producers of food-producing animals.

32. Regulatory authorities should have in place a pharmacovigilance programme for the monitoring and reporting of adverse reactions to veterinary antimicrobial drugs, including lack of the expected efficacy related to microbial resistance. The information collected through the pharmacovigilance programme should form part of the comprehensive strategy to minimize microbial resistance.

33. In cases, where the assessment of data collected from pharmacovigilance and from other post-authorization surveillance including, if available, targeted surveillance of antimicrobial resistance, suggests that the conditions of use of the given veterinary antimicrobial drug should be reviewed, regulatory authorities shall endeavour to achieve this re-evaluation.

**Distribution of veterinary antimicrobial drugs in veterinary medicine**

34. The relevant authorities should make sure that all veterinary antimicrobial drugs used in food-producing animals are, to the extent possible:

- prescribed by a veterinarian or other suitably trained person authorized in accordance with national legislation or used under conditions stipulated in the national legislation;
- supplied only through licensed/authorized distribution systems;
- administered to animals by a veterinarian or, under the supervision of a veterinarian or other suitably trained person authorized in accordance with national legislation; and that
- proper records are kept of their administration (see Paragraph 58, Responsibilities of Veterinarians: Recording section).

**Control of advertising**

35. Advertising of veterinary antimicrobial drugs should be done in a manner consistent with prudent use guidelines and any other specific regulatory recommendation for the product.

All advertising of veterinary antimicrobial drugs should be controlled by the relevant authorities.

- The authorities should ensure that advertising of veterinary antimicrobial drugs:
  - complies with the marketing authorisation granted, in particular with the content of the summary of product characteristics, and
  - complies with each country’s national legislation.

**Training of users of veterinary antimicrobial drugs**

36. Training should be undertaken to assure the safety to the consumer of animal derived food and therefore the protection of public health. Training should involve all the relevant professional organisations, regulatory authorities, the pharmaceutical industry, veterinary schools, research institutes, professional associations and other approved users such as farmers and producers of food animals and should focus on:

- information on disease prevention and management strategies to reduce the need to use veterinary antimicrobial drugs;
- relevant pharmacokinetic and pharmacodynamic information to enable the veterinarian to use veterinary antimicrobial drugs prudently;
• the ability of veterinary antimicrobial drugs to select for resistant microorganisms in food-producing animals that may contribute to animal or human health problems; and
• the need to observe responsible use recommendations and using veterinary antimicrobial drugs in animal husbandry in agreement with the provisions of the marketing authorisations and veterinary advice.

Development of research
37. The relevant authorities should encourage public and private research to:
• improve the knowledge about the mechanisms of action of antimicrobials in order to optimise the dosage regimens and their efficacy;
• improve the knowledge about the mechanisms of selection, emergence and dissemination of resistance determinants;
• develop practical models for applying the concept of risk analysis to assess the public health concern precipitated by the development of resistance;
• further develop protocols to predict, during the authorisation process, the impact of the proposed use of the veterinary antimicrobial drugs on the rate and extent of resistance development; and
• develop and encourage alternative methods to prevent infectious diseases.

Collection and destruction of unused veterinary antimicrobial drugs
38. The relevant authorities should develop effective procedures for the safe collection and destruction of unused or out-of-date veterinary antimicrobial drugs.

RESPONSIBILITIES OF THE VETERINARY PHARMACEUTICAL INDUSTRY

Marketing authorisation of veterinary antimicrobial drugs for food-producing animals
39. It is the responsibility of the veterinary pharmaceutical industry:
• to supply all of the information requested by the national regulatory authority in order to establish objectively the quality, safety and efficacy of veterinary antimicrobial drugs; and
• to ensure the quality of this information on the basis of the implementation of procedures, tests and trials in compliance with the provisions of good manufacturing, good laboratory and good clinical practices.

Marketing and export of antimicrobial veterinary drugs
40. Only officially licensed/authorized veterinary antimicrobial drugs should be marketed, and then only through approved distribution systems.
• Only veterinary antimicrobial drugs meeting the quality standards of the importing country should be exported from a country in which the products were produced;
• The information necessary to evaluate the amount of veterinary antimicrobial drugs marketed should be provided to the national regulatory authority.

Advertising
41. It is the responsibility of the veterinary pharmaceutical industry to advertise veterinary antimicrobial drugs in accordance with the provisions of Paragraph 35 on the Responsibilities of the Regulatory Authorities, Control of Advertising and to not inappropriately advertise antimicrobials directly to the food animal producer.
Training

42. It is the responsibility of the veterinary pharmaceutical industry to participate in the training of users of veterinary antimicrobial drugs as defined in Paragraph 36.

Research

43. It is the responsibility of the veterinary pharmaceutical industry to contribute to the development of research as defined in Paragraph 37.

RESPONSIBILITIES OF WHOLESALE AND RETAIL DISTRIBUTORS

44. Retailers distributing veterinary antimicrobial drugs should only do so on the prescription of a veterinarian or other suitably trained person authorized in accordance with national legislation and all products should be appropriately labelled.

45. Distributors should encourage compliance with the national guidelines on the responsible use of veterinary antimicrobial drugs and should keep detailed records of all antimicrobials supplied according to the national regulations including:
   - date of supply
   - name of prescribing veterinarian
   - name of user
   - name of medicinal product
   - batch number
   - quantity supplied

46. Distributors should participate in the training of users of veterinary antimicrobial drugs as defined in Paragraph 36.

RESPONSIBILITIES OF VETERINARIANS

47. The veterinarian is responsible for identifying recurrent disease problems and developing alternative strategies to prevent or treat infectious disease. These may include changes in husbandry conditions and vaccination programs where vaccines are available.

48. Veterinary antimicrobial drugs should only be prescribed for animals under his/her care, which means that:
   - the veterinarian has been given responsibility for the health of the animal or herd/flock by the producer or the producer’s agent;
   - that responsibility is real and not merely nominal;
   - that the animal(s) or herd/flock have been seen immediately before the prescription and supply, or recently enough for the veterinarian to have personal knowledge of the condition of the animal(s) or current health status of the herd or flock to make a diagnosis and prescribe; and
   - the veterinarian should maintain clinical records of the animal(s) or the herd/flock.

49. It is recommended that veterinary professional organizations develop for their members species-specific clinical practice guidelines on the responsible use of veterinary antimicrobial drugs.

---

5 Under some circumstances, this may refer to a suitably trained person authorized in accordance with national legislation.
50. Veterinary antimicrobial drugs should only be used when necessary and in an appropriate manner:
   - A prescription for veterinary antimicrobial drugs must precisely indicate the treatment regimen, the dose, the dosage intervals, the duration of the treatment, the withdrawal period and the amount of antimicrobial to be delivered depending on the dosage, the number, and the weight of the animals to be treated;
   - All veterinary antimicrobial drugs should be prescribed and used according to the conditions stipulated in the national legislation.

51. The appropriate use of veterinary antimicrobial drugs in practice is a clinical decision which should be based on the experience and local expertise of the prescribing veterinarian, and the accurate diagnosis, based on adequate diagnostic procedures. There will be occasions when a group of animals, which may have been exposed to pathogens, may need to be treated without recourse to an accurate diagnosis and antimicrobial susceptibility testing in order to prevent the development of clinical disease and for reasons of animal welfare.

52. Determination of the choice of a veterinary antimicrobial drug by:
   - The expected efficacy of the treatment based on:
     - the clinical experience of the veterinarian
     - the spectrum of the antimicrobial activity towards the pathogens involved
     - the epidemiological history of the rearing unit particularly in regards to the antimicrobial resistance profiles of the pathogens involved. Ideally, the antimicrobial profiles should be established before the commencement of treatment. Should a first antimicrobial treatment fail or should the disease recur, the use of a second veterinary antimicrobial drug should be based on the results of microbiological tests.
     - the appropriate route of administration
     - results of initial treatment
     - known pharmacokinetics/tissue distribution to ensure that the selected veterinary antimicrobial drug is active at the site of infection
     - prognosis
   - The need to minimize the adverse health impact from the development of microbial resistance based on:
     - the choice of the activity spectrum of the veterinary antimicrobial drug
     - the targeting of specific microorganism
     - known or predictable susceptibilities using antimicrobial susceptibility testing
     - optimized dosing regimens
     - the use of effective combinations of veterinary antimicrobial drugs
     - the importance of the antimicrobial drugs to veterinary and human medicine, and
     - the route of administration

53. If the label conditions allow for some flexibility, the veterinarian should consider a dosage regimen that is long enough to allow an effective recovery of the animal but is short enough to limit the selection of resistance in foodborne and/or commensal microorganisms.

**Off-label use**

54. The off-label use of a veterinary antimicrobial drug may be permitted in appropriate circumstances and should be in agreement with the national legislation in force including the administrative withdrawal periods to be used. It is the veterinarian’s responsibility to define the conditions of responsible use in such a case including the therapeutic regimen, the route of administration, and the duration of the treatment. Off-label use of antimicrobial growth promoters should not be permitted.
Recording
55. Records on veterinary antimicrobial drugs should be kept in conformity with national legislation. Veterinarians may refer to recording information as covered in the relevant national legislation. 6

In particular, for investigation of antimicrobial resistance, veterinarians should:

- record the antimicrobial susceptibility testing results;
- investigate adverse reactions to veterinary antimicrobial drugs, including lack of expected efficacy due to antimicrobial resistance, and report it, as appropriate, to the regulatory authorities.

56. Veterinarians should also periodically review farm records on the use of veterinary antimicrobial drugs to ensure compliance with their directions.

Training
57. Veterinary professional organizations should participate in the training of users of veterinary antimicrobial drugs as defined in Paragraph 36.

RESPONSIBILITIES OF PRODUCERS
58. Producers are responsible for preventing disease outbreaks and implementing health and welfare programmes on their farms. They may, as appropriate, call on the assistance of their veterinarian or other suitably trained person authorized in accordance with national legislation. All people involved with food-producing animals have an important part to play in ensuring the responsible use of veterinary antimicrobial drugs.

59. Producers of food-producing animals have the following responsibilities:

- to use veterinary antimicrobial drugs only when necessary and not as a replacement for good management and farm hygiene, or other disease prevention methods such as vaccination;
- to implement a health plan in cooperation with the veterinarian in charge of the animals that outlines preventative measures (e.g. mastitis plan, worming and vaccination programmes, etc.);
- to use veterinary antimicrobial drugs in the species, for the uses and at the doses on the approved labels and in accordance with the prescription, product label instructions or the advice of a veterinarian familiar with the animals and the production site;
- to isolate sick animals and dispose of dead or dying animals promptly under conditions approved by relevant authorities;
- to comply with the storage conditions of veterinary antimicrobial drugs according to the approved product labelling;
- to address hygienic conditions regarding contacts between people (veterinarians, breeders, owners, children) and the animals treated;
- to comply with the recommended withdrawal periods to ensure that residue levels in animal derived food do not present a risk for the consumer;
- to not use out-of-date veterinary antimicrobial drugs and to dispose of all unused veterinary antimicrobial drugs in accordance with the provisions on the product labels;
- to inform the veterinarian in charge of the unit of recurrent disease problems;
- to maintain all clinical and laboratory records of microbiological and susceptibility tests if required by the national regulatory authority. These data should be made available to the veterinarian in charge of treating the animals in order to optimize the use of veterinary antimicrobial drugs.

---

6 Veterinarians can also refer to the “Recommended International Code of Practice for Control of the Use of Veterinary Drugs CAC/RCP 38-1993.”
To keep adequate records of all veterinary antimicrobial drugs used, including the following:
- name of the veterinary antimicrobial drug/active substance and batch number
- name of supplier
- date of administration
- identification of the animal or group of animals to which the veterinary antimicrobial drug was administered
- clinical conditions treated
- quantity and duration of the antimicrobial agent administered
- withdrawal periods
- result of laboratory tests
- result of treatment
- name of the prescribing veterinarian or other suitably trained person authorized in accordance with national legislation.

To ensure sound management of animal wastes and other materials to avoid dissemination of antimicrobial agents and resistance determinants into the environment;

To prevent the unnecessary contact with and transmission of resistant bacteria to all personnel, including farm workers;

To assist the relevant authorities in surveillance programs related to antimicrobial resistance.

CONCLUSIONS
60. Veterinary antimicrobial drugs are very important tools for controlling a great number of infectious diseases in both animals and humans. It is vital that all countries put in place the appropriate systems to ensure that veterinary antimicrobial drugs are manufactured, marketed, distributed, prescribed and used responsibly, and that these systems are adequately audited.

61. This document is designed to provide the framework that countries may implement in accordance with their capabilities but within a reasonable period of time. A stepwise approach may be appropriate for a number of countries to properly implement all of the elements in this document.

62. The continued availability of veterinary antimicrobial drugs, which are essential for animal welfare and animal health and consequently human health, will ultimately depend on the responsible use of these products by all those involved in the authorisation, production, control, distribution and use of antimicrobials in food-producing animals.

ENDNOTES:


# List of Abbreviations Used in This Code

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADI</td>
<td>Acceptable Daily Intake</td>
</tr>
<tr>
<td>CAC</td>
<td>Codex Alimentarius Commission</td>
</tr>
<tr>
<td>CAC/RCP</td>
<td>Codex Alimentarius Commission/Recommended Code of Practice</td>
</tr>
<tr>
<td>CCRVDF</td>
<td>Codex Committee on Residues of Veterinary Drugs in Foods</td>
</tr>
<tr>
<td>FAO</td>
<td>Food and Agriculture Organization of the United Nations</td>
</tr>
<tr>
<td>MRL</td>
<td>Maximum Residue Limit</td>
</tr>
<tr>
<td>OIE</td>
<td>Office International des epizooties/International Office of Epizooties</td>
</tr>
<tr>
<td>VICH</td>
<td>International Cooperation on Harmonization of Technical Requirements for Registration of Veterinary Medicinal Products</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
</tbody>
</table>
GLOSSARY AND DEFINITIONS OF TERMS

Veterinary Antimicrobial Drug
Veterinary antimicrobial drug(s) refers to naturally occurring, semi-synthetic or synthetic substances that exhibit antimicrobial activity (kill or inhibit the growth of microorganisms). Where anticoccidial products have antibacterial activity, they should be considered as veterinary antimicrobial drugs, except where this is precluded by national legislation.

Disease Treatment/Therapeutic Use
Treatment/Therapeutic Use refers to use of an antimicrobial(s) for the specific purpose of treating an animal(s) with a clinically diagnosed infectious disease or illness.

Disease Prevention/Prophylactic Use
Prevention/Prophylactic Use refers to use of an antimicrobial(s) in healthy animals considered to be at risk of infection or prior to the onset of clinical infectious disease. This treatment includes:

- control of the dissemination of a clinically diagnosed infectious disease identified within a group of animals, and
- prevention of an infectious disease that has not yet been clinically diagnosed.

Growth Promotion
Growth Promotion refers to the use of antimicrobial substances to increase the rate of weight gain and/or the efficiency of feed utilization in animals by other than purely nutritional means. The term does NOT apply to the use of antimicrobials for the specific purpose of treating, controlling, or preventing infectious diseases, even when an incidental growth response may be obtained.
# PRIORITY LIST OF VETERINARY DRUGS PROPOSED FOR EVALUATION OR RE-EVALUATION BY JECFA

<table>
<thead>
<tr>
<th>Name of compound</th>
<th>Question/s to be answered</th>
<th>Data availability</th>
<th>Proposed by</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Evaluation</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colistin</td>
<td>Establish ADI and recommend MRLs</td>
<td>Unknown</td>
<td>Korea</td>
</tr>
<tr>
<td><strong>Re-evaluation</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Triclabendazole</td>
<td>Establish MRLs in cattle, sheep and goat tissues</td>
<td>June 2005</td>
<td>Australia</td>
</tr>
<tr>
<td>Melengestrol acetate</td>
<td>Re-calculation of MRLs and TMDI</td>
<td>2004 (available)</td>
<td>JECFA</td>
</tr>
<tr>
<td>Tylosin</td>
<td>Establish ADI and recommend MRLs in poultry tissues</td>
<td>Unknown</td>
<td>Thailand</td>
</tr>
<tr>
<td>Erythromycin</td>
<td>Establish ADI and recommend MRLs in poultry tissues</td>
<td>Unknown</td>
<td>Thailand</td>
</tr>
<tr>
<td>Enrofloxacin</td>
<td>Establish ADI and recommend MRLs in poultry and swine tissues and shrimp</td>
<td>Unknown</td>
<td>Thailand</td>
</tr>
<tr>
<td>Trichlorfon</td>
<td>Toxicological evaluation addressing concerns raised by the EC</td>
<td>Available</td>
<td>CCRVDF</td>
</tr>
<tr>
<td>Ractopamine</td>
<td>Re-calculation of MRLs and TMDI taking decision of the 15th CCRVDF into account regarding rounding practices</td>
<td>Available</td>
<td>US</td>
</tr>
</tbody>
</table>